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Abbreviations  
AUC   area under time-activity curve 
BBB  blood–brain barrier 
Bmax  the maximum binding 
CER  cerebellum 
CHO cells Chinese hamster ovary cells 
cLogP  calculated n‑octanol–water partition coefficient 
CNS  central nervous system 
CSF   cerebrospinal fluid 
CTX  neocortex 
DCM  dichloromethane 
DIAD  diisopropyl azodicarboxylate 
DIPEA  N,N-diisopropylethylamine 
DMF  N,N-dimethyl formamide 
DMSO  dimethyl sulfoxide 
DPM  disintegrations per minute 
EGTA  ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid 
EOB  end of bombardment 
EOS   end of synthesis 
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ESI–MS electrospray ionization mass spectra 
FAB–MS fast atom bombardment mass spectra 
FOV   field of view 
FR   flux ratio 
FWHM  full-width at half-maximum 
GPCR  G-protein coupled receptor 
HATU  N,N,N’,N’-tetramethyl-O-(7-aza-benzotriazol-1-yl) uronium 
   hexafluorophosphate 
HEPES  4-(2-hydroxyethyl)-1-piperazinethanesulfonic acid 
HIP  hippocampus 
HOBt   1-hydroxybenzotriazole monohydrate 
HPLC  high-performance liquid chromatography 
HRMS  high-resolution mass spectra 
% ID/mL  percentage of injected radioligand dose per unit volume of tissue 
Kd,   dissociation constant 
Ki,   inhibition constant 
LC   locus coeruleus 
MDR1   multidrug resistance protein 1 
MOM   methoxymethyl 
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MPFC   medial prefrontal cortex 
MRI  magnetic resonance imaging 
NaHMDS  sodium hexamethyldisilazane 
OXR  orexin receptor; OX1R, orexin-1 receptor; OX2R, orexin-2 receptor 
PET  positron emission tomography 
Pd2(dba)3  tris(dibenzylideneacetone)dipalladium(0) 
P-gp   P-glycoprotein 
ROI  regions of interest 
rt  room temperature 
SD  standard deviation 
TEA  triethylamine 
THA   thalamus 
THF   tetrahydrofuran 
TMN  tuberomammilliary nucleus 
tR  retention time 
WSC   1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
Xant phos  4,5-bis (diphenylphosphino)-9,9-dimethylxanthen 
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1. Summary 
Orexin receptors (OXRs) in the brain have been implicated in diverse physiological and 
neuropsychiatric conditions. Here we describe the design, synthesis, and evaluation of OXR 
ligands related to (1R,2S)-2-(((2-Methyl-4-methoxymethylpyrimidin-5-yl) oxy)methyl) 
-N-(5-fluoropyridin-2-yl)-2-(3-fluorophenyl)cyclopropanecarboxamide (9a) applicable to 
positron emission tomography (PET) imaging. Structural features were incorporated to 
increase binding affinity for OXRs, to enable carbon-11 radiolabeling, and to adjust 
lipophilicity considered optimal for brain penetration and low nonspecific binding. 9a 
displayed nanomolar affinity for OXRs and autoradiography using rat brain sections showed 
that specific binding of [11C]9a distributed primarily to neocortical layer VI and 
hypothalamus, consistent with reported localizations of orexin-2 receptors (OX2Rs). In vivo 
PET study of [11C]9a demonstrated moderate uptake of radioactivity into rat and monkey 
brains under deficiency or blockade of P-glycoprotein, and distribution of PET signals in the 
brain was in agreement with autoradiographic data. Our approach and findings have provided 
significant information for development of OX2R PET tracers. 
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2. Background 
2.1. G-protein coupled receptors (GPCRs).  
G-protein coupled receptors (GPCRs) are the largest and most diverse group of membrane 
receptors in eukaryotes that mediate the majority of cellular responses to hormones and 
neurotransmitters. All GPCRs contain seven membrane-spanning segments, which are 
separated alternating intra- and extracellular loop regions. In vertebrates, GPCRs are 
commonly categorized into five families; rhodopsin, secretin, glutamate, adhesion, and 
Frizzled/Taste2.1 Binding of a signaling molecule to a GPCR results in G protein activation, 
which in turn triggers the production of any number of second messengers. Through this 
sequence of events, GPCRs help regulate an incredible range of body functions, from 
sensation to growth to hormone responses. Humans alone have nearly 1,000 different GPCRs, 
and each one is highly specific to a particular signal. Additionally GPCRs have greatly 
affected mordern drug development. It has been estimated that more than half of available 
drugs on the market target GPCRs. 
 
2.2. Orexin receptors and their ligand.  
Orexin or hypocretin receptors (OXRs) are found as one of orphan GPCRs,2 and identified 
that mediate the central actions of the endogenous neuropeptides orexin-A/hypocretin-1 (33 
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amino acid residues long) and orexin-B/hypocretin-2 (28 amino acid residues long) produced 
in the posterior and lateral hypothalamus.3,4  
2.2.1. Identification of orexin; Completely different approaches were taken by two 
independent groups converged on the identification of orexin/hypocretin peptide in 1998.3,5 de 
Lecea et al. identified the pro-hormone preprohypocretin, and its peptide products hypocretin 
1 (Hcrt1/orexin-A) and hypocretin 2 (Hcrt2/orexin-B), by nucleotide sequencing.5 Meanwhile 
Sakurai et al. identified orexin-A and orexin-B as endogeneous ligand for two orphan GPCRs, 
orexin-1 receptor (OX1R, also known as Hcrt1) and orexin-2 receptor (OX2R, Hcrt2 
receptors), by using the technique of orphan receptor cloning.3 Orexins constitute a novel 
peptide family, with no homology with any previously described peptides. Both 
neuropeptides are derived from the same precursor, preproorexin, by proteolytic processing 
(Figure 1A).6 
Orexins have been known as the “feeding center”, intracerebroventicular administration of 
orexin-A and orexin-B was performed to observe the action of these peptides on feeding 
behavior. Orexins are found to increase food intake in rats in a dose-dependent manner; this 
was the reason these peptides were named “orexin” after the Greek word orexis, which means 
appetite.3 
2.2.2. Identification of orexin; Mammalian orexin-A is a 33-amino-acid peptide with two 
intrachain disulfide bonds, while mammalian orexin-B is a 28-amino-acid, C-terminally 
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amidated linear peptide (Figure 1B).6 Strong homology between orexin-A and orexin-B is 
found in their C terminal halves. Orexin-A and orexin-B are both derived from a common 
precursor, preproorexin, which is encoded by a gene composed of two exons and an 
intervening intron located at 17q21 in human.3,7 Preproorexin is a 130–131-residue 
(depending on the species) polypeptide, which has a typical secretory signal sequence at its 
N-terminus, and is proteolytically cleaved to form mature orexin-A and -B (Figure 1).  
2.2.3. Orexin receptors; Two orexin receptor subtypes, OX1R and OX2R, which are 
identified in mammal, have 64% amino acid identity with each other. Amino acid identities 
between the human and rat counterparts of each of these receptors are 94% for OX1R and 
95% for OX2R, indicating that both receptor genes are highly conserved between the species. 
OX1R has a 1-order-of magnitude greater affinity for orexin-A compared with orexin-B. 
OX2R has similar affinity for both orexin-A and orexin-B (Figure 1). OX1R is coupled 
exclusively to the Gq subclass of heterotrimeric G proteins, whereas OX2R is coupled to both 
Gi/o and Gq when expressed in cell lines.8 
2.2.4. Distribution of Orexin receptors; In the central nervous system, in situ hybridization 
studies have demonstrated that both orexin receptor mRNAs are expressed in regions which 
contain dense orexin innervations. OX1R and OX2R mRNAs show partially overlapping but 
largely distinct and complementary distribution patterns, suggesting that they play different 
physiological roles for each receptor subtype. It has been documented that mRNAs encoding 
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OX1R and OX2R are expressed in several distinct regions of the rat brain.9,10,11 High structural 
and functional homology is also reported for rat and human OX1R and OX2R, and orexins are 
well conserved across mammalian species.12 OX2R is present with a relatively high density in 
the hippocampal CA3 region, neocortical layer VI, tuberomammilliary nucleus (TMN), 
induseum griseum, medial thalamic areas and nucleus accumbens, in distinction from 
abundant localization of OX1R to the prefrontal cortex, hippocampus, paraventricular 
thalamic nucleus, ventromedial hypothalamic nucleus, dorsal raphe nucleus, and locus 
coeruleus (LC).10 Within the brain, OX1R is most abundantly expressed in the LC, while 
OX2R is most abundantly expressed in the TMN, regions highly important for maintenance of 
arousal. These histological findings suggest that orexins and their receptors are likely to play 
a broad regulatory role in the central nervous system and could regulate feeding, autonomic 
control, sleep, memory, and the reward system. 
OX1R is also distributed in the peripheral tissues, such as kidney, adrenal, thyroid, testis, 
ovaries, and jejunum. OX2R is found in adrenal glands, lung, and pituitary.13 
However, physiological and functional role for each receptor subtype is absolutely 
unknown. 
2.2.5. Orexin–producing neurons; Orexin-producing neurons (orexin neurons) are 
exclusively localized to the lateral hypothalamic area.14,15,16 These cells diffusely project to 
the entire neuroaxis, excluding the cerebellum (Figure 2). The densest staining of 
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orexin-immunoreactive nerve endings in the brain was found in the arcuate nucleus of the 
hypothalamus, raphe nuclei, TMN and LC. Together with the tissue distribution of both 
OXRs, these observations suggest that these regions are major effector sites of orexin.  
Orexin colocalizes with dynorphin,17 galanin,18 prolactin,19 neuronal activity regulated 
pentraxin,20 and glutamate.21 Many orexin neurons express vesicular glutamate transporters, 
suggesting that many if not all orexin neurons are also glutamatergic.22,23 In contrast, orexin 
neurons do not express GAD-67 mRNA, suggesting that orexin neurons are not 
GABAergic.22 
 
2.3. Function of orexin neuron.  
Though these neuropeptides, orexin-A and -B are synthesized by only a small population of 
neurons in the posterior and lateral hypothalamus, orexins exert multiple functions 
particularly in areas related to energy homeostasis, sleep/arousal, and brain reward 
mechanisms via signaling derived from OX1R and OX2R. Activation of orexin neurons 
contributes to the promotion of maintenance of wakefulness and the modulation of rewards, 
and conversely, relative inactivity of orexin neurons induces the onset of sleep (Figure 1).24 
Preclinical and clinical studies have revealed that the orexin pathway plays a critical role in 
motivation and sleep–wake regulation.25,26 Abnormalities in the orexin signaling have been 
observed in sleep disorders such as human narcolepsy–cataplexy syndrome,27-30 irregularities 
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in central vestibular motor control,31 a variety of feeding and gastrointestinal disorders,32,33 
altered energy homeostasis,34-36 and addiction.37 In these, human narcolepsy–cataplexy has 
been highlighted as the result of orexin defficiency.28,38-39 However, functional differences 
between signaling pathways derived from OX1R and OX2R have not been completely 
elucidated yet. 
2.3.1. Narcolepsy; Narcolepsy is a sleep disorder characterized by a primary 
disorganization of behavioral states. It is characterized by the inability to maintain vigilance 
states, pathological intrusion of non-REM and/or REM sleep into wakefulness, and frequent 
transitions between states of sleep and wakefulness. Human narcolepsy patients feel excessive 
daytime sleepiness (an insurmountable urge to sleep), manifested particularly as attacks of 
falling asleep at inappropriate times (sleep attack). They often suffer from an attack called 
“cataplexy”, which is characterized by sudden weakening of postural muscle tone, which can 
range from jaw dropping and speech slurring to complete bilateral collapse of the postural 
muscles. 
The involvement of the orexins in narcolepsy is shown in some animal models. 
prepro-Orexin gene knockout mice or dogs with null mutations in the OX2R gene show 
phenotypes remarkably similar to humans with narcolepsy.38,39 Some studies elucidated that 
prepro-orexin knockout mice, orexin neuron-ablated (orexin/ataxin-3-transgenic) mice, and 
OX1R/OX2R double-knockout mice showed similar phenotypes that have strong parallels to 
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the human condition, characterized by behavioral arrests that are similar to cataplexy, 
occasional direct transitions to REM sleep from wakefulness, and highly fragmented 
sleep-wake cycles.38,40  
In human postmortem narcolepsy subjects consistently showed an 80 to 100% reduction in 
the number of neurons containing detectable prepro-orexin mRNA or orexin-like 
immunoreactivity in the hypothalamus and undetectable levels of orexin peptides in the cortex 
and pons, in which normally orexinergic projections are found.28,29  In good agreement with 
this report, undetectable levels of orexin A in the cerebrospinal fluid (CSF) of narcolepsy 
patients was presented in earlier study.41 In addition, approximately 90% of patients with 
narcolepsy show decreased orexin A levels in the cerebrospinal fluid.30 In particular, 
narcolepsy with cataplexy (narcolepsy-cataplexy) shows higher concordance with low CSF 
orexin A level. A low CSF level of orexin A is now one of the diagnostic criteria for 
narcolepsy-cataplexy according to the 2nd edition of the International Classification of Sleep 
Disorders (American Academy of Sleep Medicine, 2005). 
2.3.2. Modulating reward pathways; Orexin neurons play an essential role in modulating 
reward pathways.42 Rewarding stimuli such as cocaine, morphine and food trigger release of 
dopamine from the mesolimbic dopamine projections, and excessive activity in this pathway 
can cause addiction. Orexins enhance signaling in this reward network, and mice lacking 
orexins not only eat less but also show much less addictive behavior with morphine or 
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amphetamines.43,44 Thus, by reducing activity in reward pathways, an orexin antagonist might 
be useful in the treatment of obesity or drug addiction by reducing food or drug craving and 
the risk of relapse.  
Hence, an orexin antagonist may help people troubled by substance abuse only if it can be 
given at a dose that dampens activity in reward pathways without producing too much 
sedation or a general lack of motivation. 
 
2.4. Chemical Aspect of drug development 
2.4.1. OXR antagonist development; Due to the therapeutic potential of modulating these 
receptors, this has been an active area of research, primary for the treatment of insomnia.45-50 
Development of almorexant (1, a dual OX1–OX2R antagonist) from 
Actelion/GlaxoSmithKline was terminated at phase III clinical trial for the treatment of 
insomnia (Figure 3). SB-649868 (2a, a dual OX1–OX2R antagonist) for sleep disorders had 
proceeded to phase II clinical development prior to 1. Further advancement is exemplified by 
suvorexant (3a),51 a dual OX1–OX2R antagonist from Merck, and application of this new drug 
for the treatment of insomnia was filed for approval by United States Food and Drug 
Administration in 2012. 
Another possible use of orexin receptor antagonists includes withdrawal from drug 
addiction. SB-334867A (2b, a selective OX1R antagonist)52,53 significantly suppressed 
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morphine-induced place preference and hyperlocomotion49,50 and blocked the reinstatement of 
previously extinguished cocaine-seeking behavior and locomotor sensitization to cocaine54,55 
and decreased intravenous nicotine self-administration and the motivation to obtain the drug 
in rats.56 OX1R antagonists may have therapeutic utility in the treatment of obesity and drug 
addiction.  
2.4.2. Development of tritiated compounds for OXR imaging; A suitable radioligand would 
help examine the relationship between the therapeutic effect and receptor occupancy of this 
novel class of medicinal agents. It is of particular interest to target either OX1R or OX2R by 
synergistically using therapeutic and imaging agents. 
A few tritiated tracers, such as [3H]1,57 [3H]N-ethyl-2-[(6-methoxypyridin-3-yl)- 
(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-1-acetamide ([3H]EMPA, [3H]4),58 and 
[3H]SB674042 ([3H]5),59 are known to be usable for in vitro analysis of OXRs.  
This is consistent with reported distribution of in vitro autoradiographic labeling with 
[3H]4,58 which is selective for OX2R, and supports the notion that specific binding of a 
positron emission tomography (PET) ligand to the neocortex (particularly layer VI) could be 
an indicator of its reactivity with OX2R.  
2.4.3. Obstacles for PET probe development; However, the 3H-labeled compounds are 
inappropriate and are limited to visualize behavior of the traceability directly in vivo. PET?  
studies have provided the first quantification of receptors in the living brain and thereby 
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allowed for studies of receptor density in relation to pathophysiology. A significant 
enhancement in the clinical utility of brain PET imaging is anticipated with recent 
development of pathophysiology. In order to use PET or SPECT to identify specific brain 
receptors (or transporters) associated with particular molecule, properly radiolabeled receptor 
"ligands" (PET probes) need to be developed.  
In fact, the lack of such PET probes with high specific affinity for the target is often the 
limiting factor in the advancement of such studies. Moreover, the essential factors based on 
medicinal chemistry such as affinity, feasibility, permeability to the brain in case of the 
neuronal imaging, lipophilicity, and stability against metabolism should be considered for 
drug design and preparation for these compounds. 
2.4.4. Advantage for PET imaging; Recently, molecular imaging has been highlighted since 
it covers techniques so as to visualize a biochemical process in living organism. Prominent 
modalities are magnetic resonance imaging (MRI), optical imaging and nuclear imaging 
(SPECT, PET), with combination of currently under development. 
  SPECT (single photon emission tomography) is in similar principle to PET in its use of 
radionuclide and detection of gamma rays (photon). In contrast with PET, however, a tracer 
used in SPECT emits gamma ray (photon) that is measured directly, whereas a PET probe 
emits a positron that annihilates with electrons up to a few millimeters away, producing two 
photons to be emitted in opposite directions. A PET scanner detects these emissions 
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"coincident" in time, which provides more radiation event localization information with 
higher quantatativity and sensitivity than SPECT. One of the key advantages of PET is that 
several short-lived radionuclides, such as 11C and 18F, very typically seen in biological 
material or drug can be available with high traceability even in vivo.  
PET, which can non-invasively visualize neurotransmission system in living brains, is a 
useful tool for in vivo quantification of diverse biological processes for objectively evaluating 
effects of central nervous system (CNS) drugs in clinical trial. Indeed, as to the estimation of 
the optimal dose and the assessment of the clinical efficacy in clinical trials of the CNS drugs, 
there have been quite a few PET studies in human intended for estimating optimal doses of 
CNS agents based on their occupancy of target components. 
In case that a novel PET probe for OXR can be developed, it allows us to clarify 
physiological and functional role for each receptor subtype, OX1R and OX2R. Moreover it is 
expected to determine saturated receptor occupancy (RO) dose to avoid exposure to 
needlessly high dose and adverse event risks. The RO and dose relationship will guide setting 
of dose for other indications (e.g., drug abuse). 
2.4.5. PET probe development for OXR; So far only a small number of PET tracers, 
including [11C]BBAC ([11C]6a)60 and [11C]BBPC ([11C]6b),60 and [11C]461 have been 
evaluated for PET imaging of OXRs. However, in vivo PET studies of [11C]6a and [11C]6b did 
not demonstrate the uptake of these radioligands into the brain of rhesus monkeys.60 [11C]4 
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also showed very low uptake into the brain of a baboon as measured with PET (Figure 3).61 
Very recently, [11C]CW4 (3b),62 which has similar structure to 3a, was reported as a PET 
probe in this category. Unfortunately, it exhibited no specific binding even though excellent 
brain penetrance. Hence, a novel PET tracer for OXRs would be useful to understand the 
relationships between dose and receptor occupancy, efficacy and adverse events of therapeutic 
agents, in order to better guide the appropriate dose setting in clinical trials. Additionally, 
receptor occupancy could be used as an objective outcome measure in a therapeutic 
assessment. Therefore a reasonable non-saturated occupancy dose should then be adopted as 
the maximum dose in subsequent clinical trials. The rational setting of maximum dose will 
enable us to save time and resources. This would particularly serve evaluation of drugs for 
diseases in which functional biomarkers such as polysomnography (in case of insomnia) are 
unavailable. 
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3. Aim of This Research 
 To find appropriate chemical derivatives with high affinity for OXRs, we had performed 
high throughput screening in advance. Several classes of compounds were evaluated and a 
few of core structures were classified. We have attempted to identify suitable PET tracer 
candidates for OXRs among cyclopropane derivatives, one of our novel classes of compounds 
with relatively highly binding affinity for OX2R than for OX1R.63 We have selected several 
cyclopropane analogs 7a–12a (Figure 4) as PET tracer candidates for OX2R imaging based on 
their binding affinity, lipophilicity, feasibility for radiolabeling, and flux ratio (FR) for efflux 
transporter to maximize their ability to penetrate the blood–brain barrier (BBB) and overall 
feasibility of radiolabeling.  
Our aim of this research is to find a systematic and rational strategy for discovering suitable 
radioligands that can be used as PET tracers for imaging of OX2R in the CNS. I will devide 
and disccuss this thesis in the following two sections: 
 
PART A. I focused on the PET probe candidate selection strategy based on medicinal 
chemistry and described them. To achieve the purpose of the current research, we worked out 
our strategy as illustrated in Figure 5. In this part, a set of compounds were accordingly 
selected in consideration of their affinity for the target molecule and FR values. We also 
conducted radiosynthesis and in vitro autoradiographic evaluation of these compounds to 
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examine if they meet criteria for in vivo PET study. Through this screening flow, we tried to 
clarify the structure-activity relationship based on the specific radioligand binding in vitro 
autoradiography. All materials used here were prepared as summarized in Figures 6 and 7. 
 
PART B. In this part, I described results of pharmacological evaluation of the candidate 
compounds. The maximal number of binding sites (Bmax) for OX2R in the brain was 
calculated, and was used for estimating affinity of a compound required for PET detection of 
OX2R. I subsequently proceeded to in vivo characterization of these candidates in rats and a 
monkey in a stepwise manner, and assessed their potential as a lead for further development 
of PET tracers. 
 
Finally I integrated these experimental findings in the Conclusion section, by discussing the 
validity of our screening flow for exploring novel PET tracer candidates.  
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PART A 
4A. Methods 
4A.1. Equipments. 
Melting points were measured using a micro melting point apparatus (MP-500P; Yanaco, 
Tokyo, Japan) and are uncorrected. 1H NMR spectra were recorded on a JEOL-AL-300 
spectrometer (operating at 300 MHz, JOEL, Tokyo, Japan) or Varian Mercury 400 
spectrometer (operating at 400 MHz, Varian, Palo Alto, CA) or Bruker Avance 600 
spectrometer (operating at 600 MHz, Bruker BioSpin, Ettlingen, Germany), with 
tetramethylsilane as an internal standard. All chemical shifts (δ) were reported in parts per 
million (ppm) downfield relative to the chemical shift of tetramethylsilane. Signals are quoted 
as s (singlet), d (doublet), dt (double triplet), t (triplet), q (quartet), or m (multiplet). Fast atom 
bombardment mass spectra (FAB–MS) and high-resolution mass spectra (HRMS) were 
obtained on a JEOL-AL-300 spectrometer (JEOL) and recorded on the spectrometer. 
Electrospray ionization mass spectra (ESI–MS) were recorded on ThermoFisherScientific 
LTQ-Orbitrap XL spectrometer (ThermoFisherScientific Inc., Waltham, MA). Column 
chromatography was performed using Fuji Silysia BW-300 (300 mesh). Reverse phase HPLC 
was performed using a JASCO HPLC module (JASCO, Tokyo, Japan) equipped with YMC 
Pack Pro C18 columns (S-5 μm, 10 mm ID ×250 mm, YMC, Kyoto, Japan) utilizing a 0.1% 
triethylamine (TEA) in water/methanol or 0.1% TEA in water/acetonitrile (MeCN) for 
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semi-separative purification. Chemical purity analysis was carried out by using YMC Pack 
Pro C18 columns (S-5 μm, 4.6 mm ID ×150 mm, YMC) with UV detector at 254 nm. Under 
radio-HPLC purification and analysis, an effluent of radioactivity was monitored using a NaI 
(Tl) scintillation detector system. All chemical reagents and solvents were purchased from 
commercial sources (Sigma-Aldrich, St. Louis, MO; Wako Pure Chemical Industries, Osaka, 
Japan; Tokyo Chemical Industries, Tokyo, Japan) and used as supplied. [3H]4 was 
synthesized in PerkinElmer Life & Analytical Sciences (Waltham, MA). Tariquidar was 
purchased from Sequoia Research Products (Pangbourne, UK). 
Carbon-11 (11C) dioxide was produced by the 14N(p,α)11C nuclear reaction using a CYPRIS 
HM-18 cyclotron (Sumitomo Heavy Industry, Tokyo, Japan). If not otherwise stated, 
radioactivity was measured with an IGC-3R Curiemeter (Aloka, Tokyo, Japan). 
 
4A.2.Chemistry.63  
Preparation for all common key intermediates, carboxylic acids 18a–e, is summarized in 
Figure 6. The novel unlabeled compounds 7a–12a were synthesized according to reaction 
sequences delineated in Figure 7. Cyclopropane ring formation was carried out by the reaction 
of an appropriate phenyl acetonitrile 13 with (R)-(–)-epichlorohydrin to give lactone 14.64 
Reduction of lactone 14 with sodium borohydride readily gave corresponding diol 15, which 
could be regioselectively acetylated at the 2-methanol position by Novozyme® (lipase acrylic  
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resin from Candida Antarctica), in order to give the desired mono-acetylated compound 16. 
Mitsunobu reaction of the corresponding alcohol with various kinds of hydroxyl pyrimidines 
led to the production of 17 as an intermediate. Hydrolysis of 17 with sodium hydroxide 
(NaOH), followed by treatment with an appropriate oxidizer, afforded corresponding 
carboxylic acid 18.  
All of the selected PET tracer candidates 7a–12a were prepared in an unlabeled form. Also, 
the corresponding precursors 7b–12b for radiosynthesis were prepared, as shown in Figure 8. 
Condensation of 18 with various kinds of pyridines to form an amide bond was carried out via 
the amidation of carboxylic acid with aminopyridines or palladium coupling of carboxamide 
and chloropyridines. 
For candidates with a methoxy group, we prepared corresponding hydroxy derivative as a 
radiolabeling precursor. 8b and 11b were prepared from target molecule 8a and 11a, 
respectively, by cleavage of the methoxy group with pyridine hydrochloride. To prepare 7a 
and its precursor 7b, methoxymethyl (MOM) group was introduced prior to the first step. To 
prepare precursors of 9a and 12a, a methanol moiety on the pyrimidine ring was required. 
Therefore, hydroxy precursors, 9c and 12c were converted to 9b and 12b, respectively, in 
three steps via bromination of side chain using Br2/CHCl3; note that the reaction mainly gave 
4-bromination with a trace amount of 2,4-dibromide. Subsequent substitution for acetoxy 
group with sodium acetate followed by hydrolysis produced 9b and 12b. Moreover, 10a and 
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its precursor 10b were prepared by reacting the common starting material 18b with 
2-amino-5-iodopyridine and 2-amino-5-cyanopyridine, respectively. 
 
4A.3.Radiosynthesis.  
Radiosynthesis of [11C]7a–12a was performed using a handmade automated synthesis 
system equipped with two units for [11C]methylation and [11C]cyanation. 
The O-[11C]methyl ligands [11C]7a, [11C]8a, [11C]9a, [11C]11a, and [11C]12a were prepared 
by reacting precursor 7b, 8b, 9b, 11b, and 12b with [11C]methyl iodide ([11C]CH3I), 
respectively (Figure 8). 
[11C]CH3I was prepared by reducing cyclotron-produced [11C]CO2 with LiAlH4, followed 
by iodination with 57% hydroiodic acid.65 For generation of radiolabeled 7a, 8a, 9a, 11a, and 
12a, [11C]CH3I was trapped in a N,N-dimethylformamide (DMF) solution of precursors 7b, 
8b, 9b, 11b, and 12b, respectively, with appropriate amount of base at –15 °C. [11C]12a was 
obtained from 12b in the same manner. [11C]7a, [11C]8a, and [11C]11a were prepared from 
their precursors, 7b, 8b, and 11b, respectively, according to the procedure described for the 
synthesis of [11C]9a using K2CO3 instead of NaH. 
In case of [11C]10a, we performed [11C]cyanation of 10b to obtain [11C]10a, because both 
10a and 10b could be readily prepared in one step from their common precursor 18b. 
The identities of [11C]7a–12a were confirmed by co-injection with the corresponding 
26 
 
unlabeled 7a–12a on reverse phased–analytical HPLC. In the final product solutions, their 
radiochemical purities with higher than 99% were used for all screening. Additionally, 
specific activity of each product was calculated from the UV absorption area at 254 nm based 
on standard curves from known-concentrations of unlabeled samples in common ratio. The 
amount of carrier in the final product solution was measured by the same analytical HPLC. 
Moreover, these radioligands did not show radiolysis at room temperature (rt) for 90 min after 
formulation, indicating radiochemical stability over the period of at least one PET scan.  
 
4A.4. Measurement of Lipophilicity.  
The cLogP (calculated n‑octanol–water partition coefficient) values of tested compounds 
were determined using Daylight Software ver. 4.94 (Daylight Chemical Information Systems, 
Inc., Niguel, CA). LogD (n‑octanol–water coefficient at pH 7.4, in this thesis) values of 
selected compounds were measured by mixing 11C-labeled compound (radiochemical purity, 
>99%; about 200,000 cpm) with n-octanol (3.0 g) and phosphate buffered saline (PBS; 3.0 g, 
0.1 M, pH 7.4) in a test tube. The mixture was vortexed for 3 min at rt, followed by 
centrifugation at 2,330 ×g for 5 min. Aliquots of 1 mL of PBS and 1 mL of n-octanol were 
removed and weighed, and their radioactivity was quantified with a 1480 Wizard automatic 
γ counter (Perkin-Elmer, Waltham, MA). Sample from the remaining organic layer was 
removed and repartitioned until a consistent LogD was obtained. LogD value was calculated 
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by the following formula: LogD = Log[(cpm/g n-octanol)/(cpm/g PBS)]. (cpm; count per 
minute) All measurements were performed in triplicate.  
 
4A.5. P-gp Transcellular Transport Study. 66,67 
LLC-PK1 and LLC-MDR1 cells were seeded at a density of 4.0 ×105 cells/cm2 onto porous 
membrane filters of 24-well cell culture insert plates. Cells were cultured in 5% CO2 at 37 °C 
and were used for the transport studies 5 days after seeding. For trans-cellular transport 
experiments, each cell monolayer was pre-incubated at 37 °C for 2 h in Hank’s balanced salt 
solution containing 10 mM HEPES (HBSS buffer). 
Trans-cellular transport experiments were initiated by adding the solution of test 
compounds to the apical or basal side of the cell culture inserts. After incubation at 37 °C for 
2 h, HBSS buffer was sampled from the opposite compartment of that spiked with test 
compounds and analyzed for test compound concentration by LC–MS. 
The apparent permeability coefficient (Papp) of the test compounds were estimated using 
Equation 1, where Q, t, C0, and A represent permeated amount of test compounds, incubation 
time, initial concentration of test compounds, and membrane area, respectively. 
 Papp = Q/t/C0/A     (1) 
Both FRs across the monolayer, LLC-PK1 and LLC-MDR1 were defined according to 
Equation 2, where Papp, b to a and Papp, a to b represent the Papp in the basal-to-apical direction and 
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the apical-to-basal, and the corrected FR was defined by Equation 3. 
 FR = Papp, b to a  / Papp, a to b     (2) 
Corrected FR = (FR in LLC-MDR1 cells) / (FR in LLC-PK1 cells)  (3) 
 
4A.6. In Vitro Binding Assays for Ki Value Evaluation.  
Human OX1R or OX2R expressing CHO cells (Chinese hamster ovary cells) were 
homogenized in 20 mM HEPES buffer (pH = 7.4) containing 10 mM MgCl2 and 2 mM 
EGTA with a Polytron homogenizer (Kinematica AG, Lucerne, Switzerland). The 
homogenate was centrifuged at 1,000 ×g for 10 min at 4 °C and the supernatant was further 
centrifuged at 40,000 ×g for 45 min at 4 °C (Beckman Coulter, Fullerton, CA). The pellet was 
resuspended in the same buffer and stored at –80 °C before use.   
Cell homogenate was diluted to 250 μg/mL in 25 mM HEPES buffer (pH = 7.5) containing 
5 mM MgCl2, 1 mM CaCl2, 0.5% BSA, 0.1% sodium azide, and 0.05% Tween® 20. Twenty 
μL of membrane suspension of OX1R or OX2R containing 5 μg protein was mixed with 10 
μL of compounds, Orexin A (100 μM, Peptide Institute, Osaka, Japan) solution or vehicle and 
10 μL of [125I]-Orexin A solution (2 nM, PerkinElmer, Waltham, MA) and 60 μL of assay 
buffer (final volume: 100 μL) and the mixture incubated for 30 minutes at rt on a 96 well 
Flashplate (PerkinElmer). All reaction mixtures were discarded and washed with 200 μL of 
25 mM HEPES buffer containing 525 mM of NaCl. The radioactivity (disintegrations per 
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minute, DPM) of each well was measured using a TopCount device (PerkinElmer). The 
inhibitory activities of test compounds were calculated using the following formula: 
Inhibition % = 100 – 100 × (T – N) / (C – N) 
T: DPM in the presence of compounds (test). 
N: DPM in the presence of 10 μM Orexin A (nonspecific binding). 
C: DPM in the absence of compound (control). 
All values were determined as averages of 3 wells in a single measurement. 
 
4A.7. In Vitro Autoradiography. 
Rat brain sections (20 μm-thick, coronal) were dried up at rt and pre-incubated for 20 min 
in 25 mM HEPES buffer (pH 7.4) containing 5 mM MgCl2 and 1 mM CaCl2 at rt. After 
pre-incubation, these sections were incubated for 60 min at rt in fresh buffer with [11C]7a (7.6 
nM), [11C]8a (2.0 nM), [11C]9a (2.5 nM), [11C]10a (59 nM), [11C]11a (1.6 nM), [11C]12a (2.6 
nM), respectively. Unlabeled compounds 7a–12a (10 μM) were used to assess the nonspecific 
binding of these radioligands in the brain. After incubation, brain sections were rapidly 
washed with cold distilled water three times, and dried up at rt. An imaging plate (BAS-IP 
MS2025, Fujifilm, Tokyo, Japan) was exposed to the dried sections for 1 h. Radioactive 
standards calibrated with known amounts of [11C]7a–[11C]12a were blotted in the exposure 
process. Quantitative autoradiogram analysis was performed using a computer-assisted image 
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analyzer (Multi Gauge; Fujifilm). Optical density values were converted to fmol/mg protein 
using a computer generated regression analysis which compared film densities produced by 
tissue sections and radioactive standards. 
The following quantitative indexes of radioligand binding were determined by measuring 
autoradiographic signals: (i) ratio of radioactivities in the OX2R-enriched neocortical layer VI 
between slices untreated and treated with cold ligand as an index of total binding versus 
non-specific binding; (ii) ratio of radioactivities in the neocortical layer III-IV between slices 
untreated and treated with cold ligand as an index of saturable off-target binding versus 
non-specific binding; (iii) ratio between (i) and (ii) as an index of specific radioligand binding 
to OX2R. All regions of interest (ROIs) were defined in reference to a rat brain atlas (Edward 
G Jones, http://brainmaps.org/index.php) 
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5A.Results 
5A.1. Preparation for unlabeled compounds and their precursor.  
All compounds listed in Figure 4 were prepared in accordance with Figures 6 and 7. The 
purity of all compounds, radiolabeling precursor 7b–12b and unlabeled 7a–12a, was 
determined by an analytical HPLC method and found to be greater than 95% for all 
compounds (See Table 2). Spectrum data of all listed compounds are shown bellow. 
Additionally, HPLC conditions and charts of each compounds are attached in Figure 9. Other 
synthetic approach, which is not referred in the literature,63 is noted here. 
(1R,2S)-2-(((2,4-Dimethylpyrimidin-5-yl)oxy)methyl)-N-(5-fluoro-4-methoxypyridin-2-yl)-2
-(3-fluorophenyl)cyclopropanecarboxamide (8a). A colorless powder; mp: 158–160 °C. 1H 
NMR (400 MHz, CDCl3, δ): 1.63 (dd, J = 5.6, 8.0 Hz, 1H), 1.91 (t, J = 5.6 Hz, 1H), 2.10 (dd, 
J = 5.6, 8.0 Hz, 1H), 2.23 (s, 3H), 2.56 (s, 3H), 3.87 (s, 3H), 4.41 (d, J = 9.6 Hz, 1H), 4.51 (d, 
J = 9.6 Hz, 1H), 6.99–7.03 (m, 1H), 7.16–7.26 (m, 2H), 7.31–7.36 (m, 1H), 7.80 (d, J = 6.4 
Hz, 1H), 7.98 (d, J = 2.8 Hz, 1H), 7.99 (s, 1H), 8.28 (brs, 1H), ESI–MS: m/z 463 (M+Na). 
HRMS (FAB) calcd for C23H22F2N4O3, 441.1738; found, 441.1777. 
(1R,2S)-2-(((2,4-Dimethylpyrimidin-5-yl)oxy)methyl)-N-(5-fluoro-4-hydroxypyridin-2-yl)-2-
(3-fluorophenyl)cyclopropanecarboxamide (8b). A mixture of 8a (36 mg, 0.08 mmol) and 
pyridine hydrochloride was stirred at 120 °C for 2 h. The reaction mixture was allowed to 
cool to rt and brine was added to the reaction mixture. The mixture was extracted with ethyl 
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acetate (AcOEt), the organic layer was dried over magnesium sulfate (MgSO4), and 
evaporated in vacuo. The residue was purified by silica gel column chromatography using 
n-heptane/AcOEt (19/1 to 0/1, v/v) to give 8b (34.3 mg, 100% yield) as a colorless powder; 
mp: 132–134 °C. 1H NMR (400 MHz, CD3OD, δ): 1.59–1.68 (m, 1H), 1.84–1.96 (m, 1H), 
2.23 (s, 3H), 2.37–2.45 (m, 1H), 2.49 (s, 3H), 4.38–4.47 (m, 1H), 4.64–4.72 (m, 1H), 
6.46–6.67 (brs, 1H), 6.95–7.10 (m, 1H), 7.26–7.45 (m, 3H), 7.69 (d, J = 5.1 Hz, 1H), 8.11 (s, 
1H). HRMS (FAB) calcd for C22H20F2N4O3, 427.1582; found, 427.1544. 
(1R,2S)-2-(((2-Methyl-4-methoxymethylpyrimidin-5-yl)oxy)methyl)-N-(5-fluoropyridin-2-yl
)-2-(3-fluorophenyl)cyclopropanecarboxamide (9a). A colorless powder; mp: 168–170 °C. 
1H NMR (400 MHz, CDCl3, δ): 1.63 (dd, J = 5.2, 8.0 Hz, 1H), 1.92 (t, J = 5.2 Hz, 1H), 2.12 
(dd, J = 6.0, 8.0 Hz, 1H), 2.63 (s, 3H), 3.30 (s, 3H), 4.29 (d, J = 13.6 Hz, 1H), 4.44 (d, J = 
13.6 Hz, 1H), 4.46 (d, J = 9.6 Hz, 1H), 4.53 (d, J = 9.6 Hz, 1H), 7.01 (tdd, J = 1.2, 2.4, 8.0 
Hz, 1H), 7.18–7.24 (m, 2H), 7.34 (dd, J = 6.0, 8.0 Hz, 1H), 7.40 (ddd, J = 2.8, 9.2, 10.4 Hz, 
1H), 8.08 (dd, J = 4.0, 9.2 Hz, 1H), 8.11 (s, 1H), 8.13 (d, J = 2.4 Hz, 1H), 8.38 (brs, 1H). 
HRMS (FAB) calcd for C23H22F2N4O3, 441.1738; found, 441.1718. 
(1R,2S)-2-(((2-Methyl-4-hydroxymethylpyrimidin-5-yl)oxy)methyl)-N-(5-fluoropyridin-2-yl)
-2-(3-fluorophenyl)cyclopropanecarboxamide (9b). Compound 9b was prepared according to 
the procedure described for the synthesis of 12b using 
(1R,2S)-2-(((2-methyl-4-bromomethylpyrimidin-5-yl)oxy)methyl)-N-(5-fluoropyridin-2-yl)-2
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-(3-fluorophenyl)cyclopropanecarboxamide (100 mg, 0.21 mmol), sodium acetate (60 mg, 
0.62 mmol) in DMF (10 mL), 1 M NaOH (2 mL) in EtOH (10 mL). The product was purified 
by silica gel column chromatography using n-heptane/AcOEt (3/7, v/v) to give 9b (53 mg, 
61% yeild) as a colorless powder; mp: 73–75 °C. 1H NMR (600 MHz, CD3OD, δ): 1.56 (t, J = 
6.0 Hz, 1H), 1.85 (t, J = 6.0 Hz, 1H), 2.49 (t, J = 6.0 Hz, 1H), 2.53 (s, 3H), 4.41 (d, J = 12.0 
Hz, 1H), 4.49 (d, J = 12.0 Hz, 1H), 4.57 (d, J = 12.0 Hz, 1H), 4.66 (d, J = 12.0 Hz, 1H), 
6.98–7.04 (m, 1H), 7.32–7.36 (m, 1H), 7.36–7.39 (m, 2H), 7.44–7.50 (m, 1H), 7.90–7.95 (m, 
1H), 8.13 (s, 1H), 8.17 (brs, 1H). ESI–MS: m/z 449 (M+Na).? HRMS (FAB) calcd for 
C22H20F2N4O3, 427.1582; found, 427.1554. 
(1R,2S)-2-(((2,4-Dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-cyanopyridin
-2-yl)cyclopropanecarboxamide (10a). A colorless needle; mp: 191–193 °C. 1H NMR (400 
MHz, CDCl3, δ): 1.68 (dd, J = 5.6, 8.0 Hz, 1H), 1.95 (t, J = 5.6 Hz, 1H), 2.16 (dd, J = 6.0, 
8.0 Hz, 1H), 2.21 (s, 3H), 2.56 (s, 3H), 4.39 (d, J = 9.6 Hz, 1H), 4.50 (d, J = 9.6 Hz, 1H), 
7.02 (tdd, J = 1.2, 2.4, 8.0 Hz, 1H), 7.17 (dt, J = 2.4, 10.0 Hz, 1H), 7.24 (dt, J = 1.2, 8.0 Hz, 
1H), 7.34 (td, J = 6.0, 8.0 Hz, 1H), 7.90 (dd, J = 2.4, 8.8 Hz, 1H), 7.98 (s, 1H), 8.20 (d, J = 
8.8 Hz, 1H), 8.48 (brs, 1H), 8.56 (dd, J = 0.8, 2.4 Hz, 1H). HRMS (FAB) calcd for 
C23H20FN5O2, 418.1679; found, 418.1714. 
(1R,2S)-2-(((2,4-Dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-iodopyridin-
2-yl)cyclopropanecarboxamide (10b). A colorless powder; mp: 200–202 °C.  1H NMR (400 
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MHz, CDCl3, δ): 1.55–1.65 (m, 1H), 1.91 (t, J = 5.6 Hz, 1H), 2.05–2.15 (m, 1H), 2.21 (s, 3H), 
2.56 (s, 3H), 4.38 (d, J = 9.2 Hz, 1H), 4.49 (d, J = 9.6 Hz, 1H), 6.97–7.04 (m, 1H), 7.14–7.20 
(m, 1H), 7.21–7.28 (m, 1H), 7.29–7.37 (m, 1H), 7.86–7.94 (m, 2H), 8.35 (brs, 1H), 8.46 (brs, 
1H). HRMS (FAB) calcd for C22H20FIN4O2, 519.0693; found, 519.0651. 
(1R,2S)-2-(((2,4-Dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoro-6-met
hoxypyridin-2-yl)cyclopropanecarboxamide (11a). A colorless powder; mp: 170–171 °C. 1H 
NMR (400 MHz, CDCl3, δ): 1.61–1.67 (m, 1H), 1.92 (t, J = 5.4 Hz, 1H), 2.05–2.16 (m,1H), 
2.24 (s, 3H), 2.56 (s, 3H), 3.96 (s, 3H), 4.42 (d, J = 9.4 Hz, 1H), 4.53 (d, J = 9.4 Hz, 1H), 
6.97–7.05 (m, 1H), 7.16–7.22 (m, 1H), 7.23–7.40 (m, 3H), 7.55 (dd, J = 2.2, 8.6 Hz, 1H), 
7.94–8.03 (m, 1H). HRMS (FAB) calcd for C23H22F2N4O3, 441.1738; found, 441.1756. 
(1R,2S)-2-(((2,4-Dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoro-6-hyd
roxypyridin-2-yl)cyclopropanecarboxamide (11b). A colorless powder; mp: 101–103 °C. 1H 
NMR (400 MHz, CDCl3, δ): 1.60–1.67 (m, 1H), 1.89 (t, J = 5.6 Hz, 1H), 2.28 (s, 3H), 2.35 
(dd, J = 6.0, 8.4 Hz, 1H), 2.57 (s, 3H), 4.46 (dd, J = 9.6, 21.6 Hz, 2H), 6.89–7.01 (m, 2H), 
7.12–7.32 (m, 4H), 8.00 (s, 1H), 10.6 (brs, 1H). HRMS (FAB) calcd for C22H20F2N4O3, 
427.1582; found, 427.1579. 
(1R,2S)-2-(((2-Methyl-4-methoxymethylpyrimidin-5-yl)oxy)methyl)-N-(5-fluoropyridin 
-2-yl)-2-phenylcyclopropanecarboxamide (12a). A colorless powder; mp: 159–161 °C. 1H 
NMR (400 MHz, CDCl3, δ): 1.62–1.64 (m, 1H), 1.90 (t, J = 5.2 Hz, 1H), 2.12 (brt, J = 7.6 Hz, 
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1H), 2.62 (s, 3H), 3.27 (s, 3H), 4.27–4.55 (m, 4H), 7.30–7.46 (m, 6H), 8.08–8.12 (m, 3H), 
8.37 (brs, 1H). HRMS (FAB) calcd for C23H23FN4O3, 423.1832; found, 423.1787. 
(1R,2S)-2-(((2-Methyl-4-hydroxymethylpyrimidin-5-yl)oxy)methyl)-N-(5-fluoropyridin-2-yl)
-2-phenylcyclopropanecarboxamide (12b). A solution of bromine (40 μL, 0.76 mmol) in dry 
CHCl3 (300 uL) was added dropwise to the solution of 
(1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-N-(5-fluoropyridin-2-yl)-2-phenyl)cycl
opropanecarboxamide (12c, 150 mg, 0.38 mmol) in dry CHCl3 (3 mL) at 0 °C and the 
reaction mixture stirred at rt for 4 days. The reaction mixture was quenched with 1 M sodium 
thiosulfate and extracted with AcOEt. The organic layer was dried over MgSO4 and 
evaporated in vacuo. The residue was purified by silica gel column chromatography using 
n-heptane/AcOEt (7/3, v/v) to give (1R,2S)-2-(((2-methyl-4-bromomethylpyrimidin 
-5-yl)oxy)methyl)-N-(5-fluoropyridin-2-yl)-2-phenylcyclopropanecarboxamide (75 mg, 
41.6% yeild) as a colorless powder. 1H NMR (300 MHz, CDCl3, δ): 1.64 (dd, J = 5.2, 8.1 Hz, 
1H), 1.92 (t, J = 5.2 Hz, 1H), 2.15 (dd, J = 5.2, 8.1 Hz, 1H), 2.58 (s, 3H), 4.24 (s, 2H), 4.56 (s, 
2H), 7.30–7.43 (m, 4H), 7.48–7.54 (m, 2H), 8.05–8.12 (m, 1H), 8.12 (d, J = 3.2 Hz, 1H), 8.13 
(s, 1H), 8.33 (brs, 1H). HRMS (FAB) calcd for C22H20BrFN4O2, 471.0832; found, 471.0849. 
Sodium acetate (37 mg, 0.45 mmol) was added to the solution of the above-mentioned 
bromide (70 mg, 0.15 mmol) in DMF (2 mL) and the reaction mixture was heated at 50 °C for 
2.5 h. The reaction mixture was partitioned between AcOEt and brine, and extracted with 
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AcOEt. The organic layer was dried over MgSO4 and evaporated in vacuo. The residue was 
dissolved in MeOH (10 mL), 1 M NaOH (10 mL) was added to the reaction mixture at rt, and 
stirred for 1.5 h. The reaction mixture was partitioned between AcOEt and brine, and 
extracted with AcOEt. The organic layer was dried over MgSO4 and evaporated in vacuo. The 
residue was purified by silica gel column chromatography using n-heptane/AcOEt (4/6, v/v) 
to give 12b (49 mg, 81.0% yeild) as a colorless amorphous. 1H NMR (300 MHz, CDCl3, δ): 
1.62 (dd, J = 5.3, 7.9 Hz, 1H), 1.89 (t, J = 5.3 Hz, 1H), 2.13 (dd, J = 5.3, 7.9 Hz, 1H), 2.60 (s, 
3H), 3.89 (brs, 1H), 4.43 (d, J = 17.6 Hz, 1H), 4.44 (d, J = 9.5 Hz, 1H), 4.52 (d, J = 9.5 Hz, 
1H), 4.53 (d, J = 17.6 Hz, 1H), 7.27–7.47 (m, 6H), 8.02 (s, 1H), 8.07 (dd, J = 3.9, 9.1 Hz, 
1H), 8.13 (d, J = 2.9 Hz, 1H), 8.35 (s, 1H). HRMS (FAB) calcd for C22H21FN4O3, 409.1676; 
found, 409.1629. 
 
5A.2. Radiochemistry.  
All labeled compounds were formulated with sterile saline (3 mL) containing Tween® 80 
(100 μL) and ascorbic acid (25 mg) after HPLC purification. HPLC analytical and 
purification conditions for all labeled compounds [11C]7a–12a are shown in Figure 10 and 11, 
respectively.  
All labeled compounds were prepared with specific activity of 37–185 GBq/μmol. For 
example, [11C]methylation of 9b with [11C]CH3I under treatment with NaH proceeded 
37 
 
efficiently for 3 min at 40 °C. Semi-preparative HPLC purification for the reaction mixtures 
gave [11C]9a with 26 ± 4% (n = 5) radiochemical yields (decay-corrected) based on [11C]CO2. 
(1R,2S)-2-(((2,4-Dimethylpyrimidin-5-yl)oxy)methyl)-N-(5-fluoropyridin-2-yl)-2-(3-fluoro-4
-[11C]methoxyphenyl)cyclopropanecarboxamide ([11C]7a). Following the same manner as 
described in [11C]11a, [11C]7a was obtained from 7b (1.60 mg, 3.8 μmol). The reaction 
mixture was purified by HPLC (YMC Pack Pro C18) using the mobile phase of 
MeOH/H2O/TEA (7/3/0.01, v/v/v) at a flow rate of 4.0 mL/min to give [11C]7a (1.27 GBq 
yeild at EOS from 11.8 GBq of bombardment at EOB). The tR of [11C]7a was 9.6 min for 
purification and 5.0 min for analysis on HPLC. The synthesis time from EOB, 28.1 min; 
radiochemical yield decay-corrected), 28.0% based on [11C]CO2; radiochemical purity, > 
99%; specific activity at EOS, 70 GBq/μmol.  
(1R,2S)-2-(((2,4-Dimethylpyrimidin-5-yl)oxy)methyl)-N-(5-fluoro-4-[11C]methoxypyridin 
-2-yl)-2-(3-fluorophenyl)cyclopropanecarboxamide ([11C]8a). Following the same manner as 
described in [11C]11a, [11C]8a was obtained from 8b (1.33 mg, 3.1 μmol). The reaction 
mixture was purified by HPLC (YMC Pack Pro C18) using the mobile phase of 
MeOH/H2O/TEA (5/5/0.01, v/v/v) at a flow rate of 5.0 mL/min to give [11C]8a (1.05 GBq 
yeild at EOS from 26.6 GBq of bombardment at EOB). The tR of [11C]8a was 9.7 min for 
purification and 8.4 min for analysis on HPLC. The synthesis time from EOB, 27.5 min; 
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radiochemical yield decay-corrected, 10.7% based on [11C]CO2; radiochemical purity, > 99%; 
specific activity at EOS, 107 GBq/μmol. 
(1R,2S)-2-(((2-Methyl-4-[11C]methoxymethylpyrimidin-5-yl)oxy)methyl)-N-(5-fluoropyridin
-2-yl)-2-(3-fluorophenyl)cyclopropanecarboxamide ([11C]9a). [11C]CH3I was introduced to a 
solution of 9b (1.87 mg, 4.4 μmol) and NaH (60% in oil, 600 μg, 15 μmol) in anhydrous 
DMF (250 μL) at –15 to –20 °C. The reaction mixture was heated at 40 °C for 3 min and 
purified by HPLC to give [11C]9a. The reaction mixture was purified by HPLC (YMC Pack 
Pro C18) using the mobile phase of MeCN/H2O/TEA (4.5/5.5/0.01, v/v/v) at a flow rate of 5.0 
mL/min to give [11C]9a (1.55 GBq yeild at EOS from 22.5 GBq of bombardment at EOB). 
The tR of [11C]9a was 7.3 min for purification and 11.5 min for analysis on HPLC. The 
synthesis time from EOB, 33.5 min; radiochemical yield decay-corrected), 21.6% based on 
[11C]CO2; radiochemical purity, > 99%; specific activity at EOS, 120 GBq/μmol.  
(1R,2S)-2-(((2,4-Dimethylpyrimidin-5-yl)oxy)methyl)-N-(5-[11C]cyanopyridin-2-yl) 
-2-(3-fluorophenyl)cyclopropanecarboxamide ([11C]10a).  [11C]HCN preparation; 
[11C]HCN was synthesized by a handmade device in a two-step sequence of reaction. After 
[11C]CO2 in N2 gas from the cyclotron was trapped at –196 °C, it was heated to 50 °C, moved 
under N2 stream (flow rate of 10 mL/min) and mixed with H2 gas at a flow rate of 10 mL/min. 
The mixed gas was passed through a Ni wire tube at 400 °C in the methanizer to give a 
mixture of [11C]CH4 in the carrier gas. Then it was mixed with 5% NH3 in N2 (v/v) gas stream 
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at a flow rate of 400 mL/min and passed through Pt furnace at 950 °C to give a [11C]HCN 
containing gas, which was absorbed to the reaction solution via a bubbling tube until the 
radioactivity of the vessel reached saturation (45 s). The average of the total radioactivity 
recovered in the reaction vessel was about 70% based on [11C]CO2 at EOS. The synthesis of 
[11C]10a from [11C]HCN via [11C]CuCN was successfully carried out.68,69 
A freshly prepared solution of sodium metabisulfate (150 μL, 48 mM; 7.2 μmol) was added 
to a solution of copper(II) sulfate (100 μL, 44 mM; 6.6 μmol) at rt under N2 stream 10 min 
prior to EOB. [11C]HCN gas was bubbled into the mixture at rt and a flow rate of 400 mL/min 
until the radioactivity reached saturation. The solution was then heated to 80 °C for 2 min. A 
solution of 10b (3.5 mg, 6.8 μmol) in DMF (250 μL) was added to the reaction mixture at rt 
and heated to 165 °C for 5 min. The reaction mixture was purified by HPLC (YMC Pack Pro 
C18) using the mobile phase of MeCN/H2O/TEA (5/5/0.01, v/v/v) at a flow rate of 5.0 mL/min 
to give [11C]10a (199.4 MBq yeild at EOS from 22.7 GBq of bombardment at EOB). The tR 
of [11C]10a was 11.0 min for purification and 5.2 min for analysis on HPLC. The synthesis 
time from EOB, 33.8 min; radiochemical yield (decay-corrected), 2.8% based on [11C]CO2; 
radiochemical purity, > 99%; specific activity at EOS, 47 GBq/μmol. 
(1R,2S)-2-(((2,4-Dimethylpyrimidin-5-yl)oxy)methyl)-N-(5-fluoro-6-[11C]methoxypyridin 
-2-yl)-2-(3-fluorophenyl)cyclopropanecarboxamide ([11C]11a). [11C]CH3I was synthesized 
from cyclotron-produced [11C]CO2 as described previously.65 Briefly, [11C]CO2 was bubbled 
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into 0.04 M LiAlH4 in anhydrous THF (300 μL). After evaporation of THF, the remaining 
complex was treated with 57% hydroiodic acid (300 μL) to give [11C]CH3I, which was 
distilled at 180 °C and transferred under helium gas into a solution of 11b (1.0 mg, 2.3 μmol) 
and 0.5 M K2CO3 (5 μL, 2.5 μmol) in anhydrous DMF (300 μL) at –15 to –20 °C. After 
radioactivity reached saturation, this reaction mixture was heated at 50 °C for 3 min. The 
reaction mixture was applied to a semipreparative HPLC system. HPLC (YMC Pack Pro C18) 
purification was completed using the mobile phase of MeCN/H2O/TEA (6/4/0.01, v/v/v) at a 
flow rate of 5.0 mL/min. The radioactive fraction corresponding to the desire product was 
collected in a sterile flask, evaporated to dryness in vacuo, redissolved in 3 mL sterile saline 
and passed through a 0.22 μm Millipore filter to give [11C]11a (2.23 GBq yeild at EOS from 
18.2 GBq of bombardment at EOB). The tR of [11C]11a was 8.8 min for purification and 6.2 
min for analysis on HPLC. The specific activity of [11C]11a was calculated by comparison of 
the assayed radioactivity to the mass associated with the carrier UV peak at 254 nm. The 
synthesis time from end of bombardment (EOB), 31.5 min; radiochemical yield 
(decay-corrected), 36% based on [11C]CO2; radiochemical purity, > 99%; specific activity at 
end of synthesis (EOS), 106 GBq/μmol.  
(1R,2S)-2-(((2-Methyl-4-[11C]methoxymethylpyrimidin-5-yl)oxy)methyl)-N-(5-fluoropyridin
-2-yl)-2-phenylcyclopropanecarboxamide ([11C]12a). Following the same manner as 
described in [11C]9a, [11C]12a was obtained from 12b (2.40 mg, 5.0 μmol). The reaction 
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mixture was purified by HPLC (YMC Pack Pro C18) using the mobile phase of 
MeCN/H2O/TEA (4.5/5.5/0.01, v/v/v) at a flow rate of 5.0 mL/min to give [11C]12a (1.24 
GBq yeild at EOS from 15.7 GBq of bombardment at EOB). The tR of [11C]12a was 11.3 min 
for purification and 8.2 min for analysis on HPLC. The synthesis time from EOB, 30.1 min; 
radiochemical yield decay-corrected, 22.1% based on [11C]CO2; radiochemical purity, > 99%; 
specific activity at EOS, 101 GBq/μmol. 
 
5A.3. Measurement of Lipophilicity.  
The cLogP values and LogD values (see 4A.4) of tested compounds are listed in Table 1. 
 
5A.4. P-gp Transcellular Transport Study. 
The FR in LLC-MDR1 cells, FR in LLC-PK1 cells, and corrected FR values of tested 
compounds are measured (see 4A.5) and listed in Table 1. 
 
5A.5. In Vitro Binding Assays for Estimation of Ki Values. 
The Ki values for OX1R and OX2R of tested compounds are measured (see 4A.6) and listed 
in Table 1. 
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5A.6. In Vitro Autoradiography Study.  
Figure 12 shows representative in vitro autoradiographic images of coronal rat brain 
sections with all labeled compounds examined. Moreover, ratio of radioactivities between 
slices untreated and treated with cold compound in the OX2R-enriched neocortical layer VI (i) 
and OX2R-nonenriched layers III - IV (ii) were calculated to evaluate total and saturable 
off-target radioligand binding. Ratio of (i) to (ii) was also calculated toestimate specific 
radioligand binding to OX2R. These data are shown in Table 3. 
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6A.Discussion 
6A.1. Strategy for Appropreate PET Tracer Candidates Selection.  
One hundred and thirty compounds with potent binding affinity (inhibition constant Ki < 10 
nM) for OX2R were selected as initial PET tracer candidates. The lipophilicity of this series of 
compounds was relatively high with cLogP values ranging from 2.4 to 5.6 (cLogP values; 
4.12 ± 0.65, mean ± SD), and compounds with cLogP > 4.7 were not taken into consideration. 
We also looked at corrected FR calculated between LLC-PK1 cells and multidrug resistance 
protein 1 (MDR1) expressed in LLC-PK1 cells (LLC-MDR1) to narrow down our list of 
candidate compounds likely to penetrate BBB, since corrected FR was demonstrated to be 
well correlated to and thus highly predictive of in vivo function of P-glycoprotein (P-gp) 
located on cerebral endothelial cells.66 Therefore, compounds with FR around 3.0 or below 
were selected. Consequently, seventy-four compounds met our criteria. Based on Bmax 
values and tractability for radiolabelling, six compounds were then chosen as for PET tracer 
candidates based on their affinity and suitable characteristics as described in Figure 4.  
Since the binding potential for a ligand depends on the ratio between Bmax and dissociation 
constant (Kd, in this context equivalent to inhibition constant, Ki), we prioritized the Ki 
value.70-74 High priority was given to the affinity for OX2R over selectivity for OX2R versus 
OX1R, because these two receptor subtypes were assumed to be distinguishable by their 
distinct localizations in imaging assays. Six compounds, which have Ki values equivalent to 
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or smaller than Bmax, displayed favorable properties by meeting most of our requirements as 
listed in Table 1.  
We thereafter radiolabeled all these six compounds for subsequent autoradiographic 
characterization to validate the usefulness of selecting these criteria when screening for an 
imaging agent.  
 
6A.2. In Vitro Autoradiography Study.  
Compounds applicable to in vivo PET imaging were explored by determining their binding 
characteristics in autoradiography. Compounds yielding the ratio (i) in Table 3 smaller than 
2.0 were initially eliminated as lacking total binding affinity. Subsequently, compounds 
producing the ratio (i)/(ii) below 2.0 were excluded due to the lack of specificity for OX2R.  
 Among these radioligands, only [11C]8a and [11C]9a exhibited detectable specific binding 
to OX2R in layer VI (red arrow head) of the neocortex and hypothalamus, in line with known 
distribution of OX2R, and [11C]9a showed the highest contrast between total (Figure 12 panel 
E) and nonspecific binding (Figure 12 panel F) of all tested compounds. Moreover, the 
localizations of [11C]8a and [11C]9a signals were very similar to that of [3H]4 (Figure 12 
panels M, N).59  
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6A.3. Lipophilicity Influence on In Vitro Autoradiography Study and SAR. 
Contrast of total binding versus non-specific binding observed in autoradiography was 
nearly consistent with in vitro binding affinity (Ki) for OX2R. 7a and 10a did not produce 
signals reflecting the distribution of OX2R. Failure of staining OX2R with [11C]7a and 
[11C]10a with a larger Ki than [11C]8a and [11C]9a indicates that Ki values far below Bmax are 
required for high-contrast imaging of OX2R. Meanwhile, 11a showed Ki, lipophilicity 
(cLogP) and chemical structure similar to 8a, but it did not exhibit sufficient specific binding 
in autoradiography based on the ratio (i) / (ii). Although this discrepancy cannot be explained 
by structural diversities among 8a, 9a and 11a, LogD value for 11a was notably higher than 
those for 8a and 9a. Since 11a showed homogeneous binding to the brain slices, it is likely 
that high lipophilicity of 11a resulted in substantial non-specific binding. Therefore, an actual 
measure of lipophilicity, logD rather than cLogP is required for predicting binding properties 
in the brain. In the current experiment, preferable logD value was estimated to be 3.0 or lower. 
Hence, LogD value may serve as an informative index in search for appropriate imaging 
agents.  
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PART B 
4B. Methods 
4B.1. Receptor Binding Assay for Bmax Evaluation. 
4B.1.1. Preparation of brain homogenate; Parts of cerebral cortex which contained mainly 
layer VI were collected from Sprague-Dawley (SD) rats (male, 7 weeks old, n = 11, Charles 
River, Yokohama, Japan). Wet cerebral cortex tissues were weighed, homogenized in 0.32 M 
sucrose and 10 mM Tris-HCl (pH 8.0) on ice, and centrifuged (1,000 ×g, 4 °C, 10 min). The 
supernatant was collected and centrifuged (30,000 ×g, 4 °C, 20 min). The precipitate was 
suspended in 1 mM ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid 
(EGTA) and 50 mM Tris-HCl (pH 8.0) on ice and centrifuged (30,000 ×g, 4 °C, 20 min); this 
procedure was conducted two times. Next, the precipitate was suspended in 2 mM EGTA, 10 
mM MgCl2 and 20 mM 4-(2-hydroxyethyl)-1-piperazinethanesulfonic acid (HEPES, pH 7.4) 
on ice and centrifuged (30,000 ×g, 4 °C, 20 min); this procedure was repeated three times. 
The precipitate was suspended in 2 mM EGTA, 10 mM MgCl2 and 20 mM HEPES (pH 7.4). 
This microsomal fraction was stored as a receptor stock solution at –80 °C until use.  
4B.1.2. Binding assay; Receptor stock solution was re-suspended in binding buffer (1 mM 
CaCl2, 5 mM MgCl2, and 25 mM HEPES, pH 7.4) to a final concentration of 5 mg tissue 
eq./assay.  
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The incubation time for [3H]4 on OX2R was 60 min at 25 °C. After incubation, membranes 
were filtered onto GF/B filter and washed three times with ice–cold wash buffer (same as 
binding buffer). Each filter was placed in a vial and 5 mL of liquid scintillator reagent 
(Atomlight; PerkinElmer Life & Analytical Sciences) were added. Radioactivity was counted 
(2 min) in a liquid scintillation counter (2500, PerkinElmer Life & Analytical Sciences).  
Saturation isotherms were determined by addition of various concentrations of [3H]4 
(5–1280 nM). Nonspecific bindings for [3H]4 was measured in the presence of 0.1 mM 
unlabeled 4. Bmax was calculated by Scatchard analysis of saturation isotherm experiment.  
 
4B. 2. Assessment of specificity of 9a for OXRs in autoradiography.  
All procedures were done as in the above-mentioned screening method. [11C]9a (3.6 nM) 
and unlabeled compounds 3 (20 μM) and 4 (200 nM) were used. Coronal slices were 
collected at +1.5 mm and –3.0 mm to bregma. Representative autoradiograms were acquired 
from serial brain sections, and the neocortical layer VI in each slice was encircled based on 
brain atlas. Radioactivity in this area was then measured in 8 slices (consisting of 2 slices 
generated at +1.5 mm to bregma and 6 slices at –3.0 mm to bregma, n = 3). 
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4B.3. Animals.  
SD rats at 9–11 weeks of age (male, 410–500 g) were purchased from Japan SLC 
(Shizuoka, Japan), and P-gp–knockout rats at 10 weeks of age (Mdr1a knockout rats, male, 
410–500 g) purchased from SAGE labs (St. Louis, MO). The animals were housed under a 12 
h light–dark cycle, allowed free access to food pellets and water, and used for in vivo PET 
studies. A rhesus monkey at 3 years and 8 months of age (male, 4.25 kg) was purchased from 
Japan SLC (Shizuoka, Japan). The monkey was housed in an individual cage and was 
supplied with a balanced diet and ad libitum tap water from a feeding valve. The room was 
illuminated from 7 a.m. to 9 p.m. Age and body weight of the monkey at that time of PET 
scan was 3 years and 11 months and 4.65 kg, respectively.  
The animal experiments were approved by the Animal Ethics Committee of National 
Institute of Radiological Sciences (NIRS). 
 
4B.4. Animal PET Studies. 
4B.4.1. Wild-type rats. Prior to PET scans, anatomical template images of the rat brain 
were generated by a high-resolution MRI system. Briefly, a rat was anesthetized with sodium 
pentobarbital (50 mg/kg, i.p.), and scanned with a 400 mm bore, 7 Tesla horizontal magnet 
(NIRS/KOBELCO, Kobe, Japan/Bruker BioSpin) equipped with 120 mm diameter gradients 
(Bruker BioSpin). A 72 mm diameter coil was used for radiofrequency transmission, and 
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signals were received by a 4-channel surface coil. Coronal T2-weighted MRI images were 
obtained by a fast spin–echo sequence with the following imaging parameters: repetition time 
= 8,000 ms, effective echo time = 15 ms, field of view (FOV) = 35 mm ×35 mm, and slice 
thickness = 0.6 mm. 
PET scans for anesthetized SD rats (male, 410–500 g) were performed with a small 
animal-dedicated micro PET FOCUS 220 system (Siemens Medical Solutions, Malvern, PA), 
which yields a 25.8 cm (transaxial) ×7.6 cm (axial) FOV, and a spatial resolution of 1.3 mm 
full-width at half-maximum (FWHM) at the center of FOV.75 Subsequently, list-mode scans 
were performed for 90 min. All list-mode data were sorted and Fourier-rebinned into 
2-dimensional sinograms (frames, 1 min ×4 scans, 2 min ×8 scans, 5 min ×14 scans). Images 
were thereafter reconstructed using 2-dimensional filtered back-projection with a 0.5-mm 
Hanning filter. To inject [11C]9a, a 24-gauge needle with catheter (Terumo, Tokyo, Japan) 
was placed into the rat tail vein. The injected dose of the radioligand was 78.7–189.8 MBq 
(127.6 ± 43.1 MBq, mean ± SD). Body temperature was maintained with a 37 °C plate heater 
(Bio Research Center Inc., Aichi, Japan). During the scan, the rat was maintained under 
anesthesia with 1.5% (v/v) isoflurane. For the inhibition study, unlabeled 9a (10 mg/kg, p.o., 
dissolved 9a with 5% DMSO and 10% cremophore in 10 mM HCl, in H2O) was administered 
to the rat 1 h before the radioligand injection.  
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4B.4.2. P-gp–knockout rats. PET scans for P-gp–knockout rats (male, 410–500 g) were 
performed in the same manner as in the scans for SD rats. 
4B.4.3. Rhesus monkey.  MRI images of the monkey brain were generated by an apparatus 
identical to that for the above-mentioned rat MRI. Horizontal brain MRI images were 
obtained by a gradient echo pulse sequence termed FLASH with the following imaging 
parameters: repetition time = 481 ms, effective echo time = 7.6 ms, FOV = 110 mm ×110 mm, 
slice thickness = 1.5 mm. PET scans for a monkey was performed using a high-resolution 
SHR-7700 PET camera (Hamamatsu Photonics, Shizuoka, Japan) designed for laboratory 
animals, which provides 31 transaxial slices 3.6 mm (center-to-center) apart and a 33.1 cm 
(transaxial) ×11.16 cm (axial) FOV. The spatial resolution for the reconstructed images was 
2.6 mm FWHM at the center of FOV.76 Prior to PET scans, the monkey was initially 
anesthetized with thiamylal and anesthesia was maintained using 1.5% (v/v) isoflurane. 
Following a transmission scan for attenuation correction using a 68Ge–68Ga source, dynamic 
emission scans were conducted in a 3-dimensional acquisition mode for 90 min (frames, 1 
min ×4 scans, 2 min ×8 scans, 5 min ×14 scans). Emission scan images were reconstructed 
with a 4 mm Colsher filter. [11C]9a was injected via the crural vein as a single bolus at the 
start of emission scanning. Injected dose of the radioligand was 115.5 MBq. An additional 
PET measurement was carried out by injecting a P-gp inhibitor, tariquidar (8 mg/kg/5 mL of 
saline with 10% DMSO) via the crural vein as a single slow bolus over 10 min at 0.25 h 
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before [11C]9a administration. Injected dose of the radioligand was 87.7 MBq. All PET scans 
were acquired in the same monkey.  
4B.4.4. Image acquisition and data analysis. Anatomical ROIs were manually defined on 
the striatum, thalamus, pons, and cerebellum in the PET images coregistered with MRI 
images using PMOD® software (PMOD Technologies Ltd., Zurich, Switzerland). Regional 
radioactivity in the brain was decay-corrected to the injection time and was expressed as the 
percent of injected dose (% ID/mL = % injected dose/cm3 brain) in rat experiments, and as the 
percentage standardized uptake value [% SUV = % ID/mL × body weight (g)] in monkey 
experiments.  
 
4B.5. Metabolite Study for Rat Plasma and Brain.  
After the intravenous injection of [11C]9a (330 MBq/0.1 mL), a P-gp–knockout rat (male 
Mdr1a-knockout rat weighing 450 g, identical to one of the individuals used for the PET 
imaging, male) was sacrified by decapitation at 30 min. Blood and whole brain were quickly 
removed, and the blood sample (0.5 mL) was centrifuged at 20,000 ×g for 2 min.at 4 °C to 
separate plasma. The supernatant (0.2 mL) was then collected in a test tube containing MeCN 
(0.2 mL), and resulting mixture was voltexed for 15 s and centrifuged at 20,000 ×g for 
deproteinization. The resulting supernatant was collected. Subsequently, the half of rat brain 
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was homogenized with Silent Crusher S homogenizer (Rose Scientific Ltd., Edmonton, 
Canada) in ice-cold 50% aqueous MeCN (2.5 mL) solution. The resulting homogenate was 
centrifuged at 20,000 ×g for 2 min at 4 °C. The supernatant (0.5 mL) was collected and 
resuspended with an equal volume of MeCN (0.5 mL) followed by centrifugation at 20,000 
×g for 2 min for deproteinization. Supernatants (500 μL) were analyzed by HPLC (Capcell 
Pak C18, S-5 μm, 4.6 mm ID ×250 mm, Shiseido, Tokyo, Japan) combined to analytical 
radio-UPLC using the mobile phase of MeCN/H2O/TEA (5/5/0.01, v/v/v) at a flow rate of 1.5 
mL/min. Fraction of unmetabolized [11C]9a as percentage of total radioactivity (decay 
corrected) on HPLC chromatogram was calculated as: (peak area for [11C]9a/total peak area) 
×100. 
 
4B.6. GPCR Panel Assay.  
Target GPCRs were stably expressed in human embryonic kidney (HEK) 293 cells, a 
subset of which co-expressed Gqi5 chimeric G-protein (Gqi5/HEK293), to convert its Gi 
signaling to Ca2+ response.70 Thereafter GPCRs+Gqi5/HEK293 and Gqi5/HEK293 cells were 
seeded separately at 5000/25 μL/well into collagen type I-coated 384-well plates and cultured 
overnight in Dulbecco’s Modified Eagle’s Medium. Subsequently, calcium-sensitive 
fluorescent dye was added to cells and incubated for 1 h at 37 °C. 
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4B.6.1. Measurement of agonistic activity. For quantification of agonistic activity, 9a was 
added to cells and calcium response was recorded. Solutions of agonistic reference ligands 
were diluted in wells of cell plates with equal volumes (25 μL) of cell culture medium, 
calcium dye, and assay buffer. Solutions of 9a were diluted in wells of cell plates wells with 
equal volumes (25 μL each) of cell culture medium and calcium dye, resulting in final 
concentrations of 3, 10, and 30 μM, respectively. 
4B.6.2. Measurement of antagonistic activity against low or high dose of agonistic 
reference ligand. For quantification of antagonistic activity, solutions of 9a were diluted in 
wells of cell plates wells with equal volumes (25 μL each) of cell culture medium, calcium 
dye, and excess concentration of agonistic reference ligands resulting in final concentrations 
of 3, 10, and 30 μM for 9a. Cells were first incubated with 9a for 1 h at rt, and then reference 
ligands at a dose inducing either 20% (EC20) or 80% (EC80) of maximal response was added 
to detect inhibitory effects of 9a against these reference ligands. 
Ca2+ concentration was visualized in real time using a calcium indicator dye (Calcium 4; 
Molecular Devices, Sunnyvale, CA), and fluorescence was detected by the FDSS7000 device 
(Hamamatsu Photonics, Hamamatsu, Japan). 
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5B. Results 
5B.1. Bmax value of OX2R in layer VI  
We evaluated the density of OX2R in layer VI of the neocortex in the rat brain, and 
calculated Bmax of  layer VI using  [3H]4 was 6.5 nM (see 4B.1). 
 
5B.2. Specificity of Autoradiographic Labeling with [11C]9a for OX2R Versus OX1R.  
To clarify specificity of [11C]9a signals in the neocortex for OX2R versus OX1R and other 
binding elements, in vitro autoradiographic assays (see 4B. 2) were performed for rat brain 
sections under conditions with 3 (OX1R and OX2R dual antagonist) and 4 (OX2R selective 
antagonist). Specific binding of [11C]9a in the neocortical layer VI was decreased by 85% in 
the presence of 20 μM of 3 (Figure 13), and 70% in the presence of 200 nM of 4. 
 
5B.3. In Vivo PET Studies in Rats.  
5B.3.1. Control PET scan. PET scans were conducted using [11C]9a. Representative 
orthogonal PET images and time-radioactivity curves acquired in wild-type and in P-gp 
knockout rat are shown in Figure 14  PET scans were also conducted using [11C]8a, as 
shown in Figure 15. 
5B.3.2. Blocking PET scan. PET scans with blockade of saturable binding were conducted 
by pretreatment of P-gp knockout rats with unlabeled 9a (10 mg/kg, p.o) at 1 h before the 
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radioligand injection (Figure 14 B). Time-activity curves are shown in Figure 14 E, and the 
target-to-cerebellum ratios of AUC in the control and blocking PET scans are shown in Figure 
14 F. 
 
5B.4. In Vivo PET Study in A Rhesus Monkey.  
PET scans in a rhesus monkey were conducted using [11C]9a. Representative PET images 
and time-radioactivity curves are shown in Figure 16 (panels A, B) The monkey used for the 
baseline PET assay also underwent a [11C]9a-PET measurement initiated at 0.25 h after 
intravenous administration of tariquidar (XR9576, 8 mg/kg)77 (Figure 16C, D). 
 
5B.5. Ex Vivo Metabolite Study in a P-gp–knockout Rat.  
Ex vivo metabolite study was performed by using P-gp–knockout rat (identical to one of the 
individuals used for PET study), and we identified a radiometabolite which was more 
hydrophilic than parent tracer in plasma and brain. Retention times (tRs) for this metabolite 
and parent compound were 2.0 and 5.2 min, respectively. More than half of radioactivity in 
the brain was derived from the parent tracer at 30 min post injection, while less unchanged 
[11C]9a remained in plasma (see Table 5).  
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5B.6. Activity of 9a on Off-target Binding Components.  
Pharmacological profile of 9a was further investigated by GPCR panel assays. 9a (10 μM) 
was inactive on representative 24 off-target GPCRs (see 4B. 6), except its weak and modest 
antagonistic activity on cannabinoid CB1 and melatonin MT1 receptors, respectively (see 
Table 3). 
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6B. Discussion 
6B.1. Specificity of Autoradiographic Labeling with [11C]9a for OX2R Versus OX1R.  
To assess the specificity of autoradiographic binding of 9a in the neocortical layer VI for 
OX2R, [11C]9a was co-incubated with Compounds 3 (OXR-dual inhibitor) and 4 (OX2R 
specific inhibitor).  
Specific binding of [11C]9a in the neocortical layer VI was decreased by 85% in the 
presence of 20 μM of 3 (Figure 13), suggesting that specific binding sites for [11C]9a is 
primarily composed of OXRs. Addition of 200 nM of 4 to the reaction also diminished 
specific radioligand binding by 70%, and we accordingly conceived that OX2R was a major 
specific binding component for [11C]9a in the neocortex. It is noteworthy that 20 μM of 3 
should completely blocked both classes of OXRs, while 200 nM of 4 should induce selective 
inhibition of OX2R without notable reaction with OX1R, in light of their Ki values for OX1R 
and OX2R.  
 
6B.2. In Vivo PET Studies in Rats.  
PET scans were conducted using [11C]9a, because it produced the clearest contrast in 
autoradiography imaging. Meanwhile, in vitro assay indicated that 9a exhibited larger FR than 
the other selected compounds (Table 1), and therefore P-gp–knockout rats were used for the 
PET scan in addition to wild-type rats. Notable retention of radioactivity in OX2R-rich brain 
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regions in contrast with its low uptake in the cerebellum, which lacks the receptors, was 
observed in P-gp–knockout rats (n = 3) (Figure 14 panels A, C). However, differences in the 
radioligand retention in the neocortex, hippocampus, and thalamus could not be demonstrated 
clearly. Additionally, there was only minimal uptake of radioactivity into the brains of 
wild-type rats (n = 3) (Figure 14 panels B, D). To further examine the specificity and 
displaceability of [11C]9a binding in P-gp–knockout rats, a PET scan was conducted 1 h after 
oral administration of 10 mg/kg of unlabeled 9a, since pharmacological effects of orally 
administrated 9a at this dose was clearly demonstrated in our spontaneous locomotion and 
sleep efficacy tests for wild-type mice. As shown on the time–radioactivity curves (Figure 14 
panel E), pretreatment with unlabeled 9a markedly reduced the radioactivity compared to 
control (Figure 14 panel C). Radioligand retention was significantly inhibited in all brain 
regions except the cerebellum, and the distribution of radioactivity became fairly uniform 
throughout the brain. This resulted in a decrease in target-to-cerebellum ratios of radioactivity 
by the blockade (Figure 14 panel F), supporting the in vivo imaging of [11C]9a with its 
specific and saturable binding sites in the brain. 
Additional PET scans were conducted using [11C]8a in P-gp–knockout rat and wild-type rat, 
respectively. [11C]8a showed rapid clearance, and minimal retention in the brain. Overall, 
[11C]8a showed time–radioactivity curves similar to [11C]9a, but there was however relatively 
lower retention than [11C]9a (Figure 15).  
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Additionally, [11C]9a yielded a larger ratio of (i) to (ii) than [11C]8a as shown in Table 3, 
indicating high specific binding of [11C]9a to OX2R in the layar VI and lateral cortex relative 
to [11C]8a. As it is conceivable that 9a would be more preferable than 8a as a PET imaging 
agent, 9a was further characterized in a PET study using a non-human primate. 
 
 6B.3. In Vivo PET Study in A Rhesus Monkey.  
The radioactivity in all brain regions peaked at 30 s after intravenous [11C]9a injection 
(Figure 16 A, B), followed by a rapid decline and low level retention in the brain (Figure 16 
B), suggesting that the radioactivity was rapidly cleared from the brain by P-gp transporter in 
the initial phase of the scan. To examine this notion, an additional PET scan with [11C]9a was 
conducted under blockade of P-gp transporter. Pretreatment with tariquidar markedly 
increased the uptake of radioactivity into the brain compared to the baseline data.  
Similar to in vivo PET data in P-gp-knockout rats (Figure 16 panel C), radioactivity 
retention was the highest in the neocortex, implying that PET signals in the brain of the 
tariquidar-treated monkey may reflect distribution of OX2R. As indicated by autoradiography 
and PET results, [11C]9a had affinity for OX2R sufficient for in vivo PET imaging, but its 
poor BBB permeability and rapid clearance from the brain did not allow us to sensitively 
detect OXRs except for the brains of animals deficient in P-gp or treated with a P-gp inhibitor, 
highlighting the significance of FR values for efflux transporters. 
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6B.4. Activity of 9a on Off-target Binding Components.  
In consideration of the concentration of 9a reacted here, it is unlikely that a significant 
portion of [11C]9a at much lower concentrations in autoradiographic and PET experiments 
reacted with CB1. In addition, distribution of MT178 is distinct from that of OXRs, and 
therefore autoradiographic binding of [11C]9a to MT1 in the neocortex is presumed to be 
negligible. 
These data are consistent with autoradiographic observations indicating that specific 
binding of [11C]9a is attributable to its interaction with OX2R, although the possibility that 9a 
binds to GPCRs and non-GPCR components unexamined here could not be ruled out. On the 
basis of these in vitro results, we further evaluated [11C]8a and [11C]9a using in vivo PET 
imaging. 
 
6B.5. Radiometabolite. 
Ex vivo metabolite study data indicate that in vivo PET signals in the brains of 
P-gp-knockout rats (Figure 14 panel A, C) were composed of [11C]9a and its metabolite.?  
Although this radioactive metabolite was not identified, it might enter the brain influencing 
the image contrast, especially in the late phase of the scan. Therefore, it is required for an 
adequate PET probe to be metabolically stable and/or to generate brain-entering 
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radiometabolites during the PET scan. In this context, it would be of great significance to 
improve the biostability of 9a by structural modifications. 
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7.Conclusions 
  We developed a novel series of cyclopropane derivatives that potentially set the path for the 
development of future potent PET imaging tracers for OXRs. Based on affinity (Ki ≤ Bmax = 
6.5 nM), lipophilicity (2.4 < cLogP < 4.7), and efflux property of P-gp transporter (FR ≤ 3), 
we selected and radiolabeled several compounds as PET tracer candidates. Among them, 
[11C]9a showed specific binding for OXRs indicated by both in vitro autoradiography of rat 
brain slices and in vivo PET imaging of P-gp–knockout rats, along with the blockade of 
radioligand binding by unlabeled compounds and insignificant reactivity with GPCRs other 
than OXRs. The Bmax value for the receptors obtained from in vitro binding assays enabled us 
to estimate correctly the affinity of a ligand required for producing a sufficient imaging 
contrast, and also the lipophilicity (measured as Log D value) of the compounds had impact 
on the performance of the radioligands in autoradiographic imaging well. According to the 
autoradiographic data of [11C]8a and [11C]9a (Figure 12 panels C, E), a compound with the 
Bmax /Ki ratio of 5.0 or higher seems to be required for PET tracer candidate in order to detect 
specific binding to OX2R.70-72 By characterizing binding profile of 9a, it has potential to 
visualize neocortical OX2R with adequate specificity (Figure 12). For in vivo visualization of 
OX2R in the brain, the permeability into the CNS, which could be estimated by FR and 
lipophilicity, was equally important (Figures 14, 16). Moreover robust metabolic stability is 
required for further improvement (Table 3). We could not identify a PET tracer that can be 
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used to clearly visualize OX2R in wild-type rat and non-human primate. However, we 
succeeded in clarifying the preferred profile for an OX2R PET tracer. Hence, our approach 
and findings have provided substantial insights into the development of next-generation 
OX2R PET tracers. 
64 
 
8. References  
(1) Rosenbaum, D. M.; Rasmussen, S. G.; Kobilka, B. K. The structure and function of 
G-protein-coupled receptors. Nature 2009, 459, 356-363. 
(2) Civelli, O.; Saito, Y.; Wang, Z.; Nothacker, H.-P.; Reinscheid, R. K. Orphan GPCRs and 
their ligands. Pharmacol. Ther. 2006, 110, 525 – 532. 
(3) Sakurai, T.; Amemiya, A.; Ishii, M.; Matsuzaki, I.; Chemelli, R. M.; Tanaka, H.; 
Williams, S. C.; Richardson, J. A.; Kozlowski, G. P.; Wilson, S.; Arch, J. R. S.; Buckingham, 
R. E. C.; Haynes, A. C.; Carr, S. A.; Annan, R. S.; McNulty, D. E.; Liu, W. -S.; Terrett, J. A.; 
Elshourbagy, N. A.; Bergsma, D. J.; Yanagisawa, M. Orexins and Orexin Receptors: A 
Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate 
Feeding Behavior. Cell 1998, 92, 573–585.  
(4) van den Pol, A. N.; Gao, X. -B.; Obrietan, K.; Kilduff, T. S.; Belousov, A. B. Presynaptic 
and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic 
peptide, hypocretin/orexin. J., Neurosci. 1998, 18, 7962–7971. 
(5) de Lecea, L.; Kilduff, T. S.; Peyron, C.; Gao, X.; Foye, P. E.; Danielson, P. E.; Fukuhara, 
C.; Battenberg, E. L.; Gautvik, V. T.; Bartlett, F. S.; Frankel, W. N.; van den Pol, A. N.; 
Bloom, F. E.; Gautvik, K. M.; Sutcliffe, J. G. The hypocretins: hypothalamus-specific 
peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 322–327. 
65 
 
(6) Sakurai, T. Reverse pharmacology of orexin: from an orphan GPCR to integrative 
physiology. Regul. Pept. 2005, 126, 3–10. 
(7) Sakurai, T.; Morigushi, T.; Furuya, K.; Kajiwara, N.; Nakamura, T.; Yanagisawa, M.; 
Goto, K. Structure and function of human prepro-orexin gene. J. Biol. Chem. 1999, 274, 
17771– 6. 
(8) Zhu, Y.; Miwa, Y.; Yamanaka, A.; Yada, T.; Shibahara, M.; Abe, Y.; Sakurai, T.; Goto, 
K. Orexin receptor type-1 couples exclusively to pertussis toxininsensitive G-proteins, while 
orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins. J. 
Pharmacol. Sci. 2003, 92, 259–66. 
(9) Trivedi, P.; Yu, H.; MacNeil, D. J.; Van der Ploeg, L. H. T.; Guan, X. -M. Distribution of 
orexin receptor mRNA in the rat brain. FEBS Lett. 1998, 438, 71–75. 
(10) Marcus, J. N.; Aschkenasi, C. J.; Lee, C. E.; Chemelli, R. M.; Saper, C. B.; Yanagisawa, 
M.; Elmquist, J. K. Differential expression of orexin receptors 1 and 2 in the rat brain. J. 
Comp. Neurol. 2001, 435, 6–25.  
(11) Lu, X. Y.; Bagnol, D.; Burke, S.; Akil, H.; Watson, S. J. Differential distribution and 
regulation of OX1 and OX2 orexin/hypocretin receptor messenger RNA in the brain upon 
fasting. Horm. Behav. 2000, 37, 335–344. 
66 
 
(12) Wright, G. J.; Cherwinski, H.; Foster-Cuevas, M.; Brooke, G.; Puklavec, M. J.; Bigler, 
M.; Song, Y.; Jenmalm, M.; Gorman, D.; McClanahan, T.; Liu, M. R.; Brown M. H.; 
Sedgwick, J. D.; Phillips, J. H.; Barclay, A. N. Characterization of the CD200 receptor family 
in mice and humans and their interactions with CD200. J. Immunol. 2003, 171, 3034–3046. 
(13) Johren, O.; Neidert, S. J.; Kummer. M.; Dendorfer, A.; Dominiak, P. Preproorexin and 
orexin receptor mRNAs are differentially expressed in peripheral tissues of male and female 
rats. Endocrinology 2001, 142, 3324–3331. 
(14) Date, Y.; Ueta, Y.; Yamashita, H.; Yamaguchi, H.; Matsukura, S.; Kangawa, K.; 
Sakurai, T.; Yanagisawa, M.; Nakazato, M. Orexins, orexigenic hypothalamic peptides, 
interact with autonomic, neuroendocrine and neuroregulatory systems. Proc. Natl. Acad. Sci. 
U S A. 1999, 96, 748–753. 
(15) Nambu, T.; Sakurai, T.; Mizukami, K.; Hosoya, Y.; Yanagisawa, M.; Goto, K. 
Distribution of orexin neurons in the adult rat brain. Brain Res. 1999, 827, 243–260. 
(16) Peyron, C.; Tighe, D. K.; van den Pol, A. N.; de Lecea, L.; Heller, H. C.; Sutcliffe, J. 
G.; Kilduff, T. S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. 
J. Neurosci. 1998, 18, 9996– 10015. 
67 
 
(17) Chou, T. C.; Lee, C. E.; Lu, J.; Elmquist, J. K.; Hara, J.; Willie, J. T.; Beuckmann, C. 
T.; Chemelli, R. M.; Sakurai, T.; Yanagisawa, M.; Saper, C. B.; Scammell, T. E. Orexin 
(hypocretin) neurons contain dynorphin. J. Neurosci. 2001, 21, RC168. 
(18) Håkansson, M.; de Lecea, L.; Sutcliffe, J. G.; Yanagisawa, M.; Meister, B. Leptin 
receptor- and STAT3-immunoreactivities in hypocretin/orexin neurones of the lateral 
hypothalamus. J Neuroendocrinol. 1999, 11, 653–663. 
(19) Risold, P. Y.; Griffond, B.; Kilduff, T. S.; Sutcliffe, J. G.; Fellmann, D. 
Preprohypocretin (orexin) and prolactin-like immunoreactivity are coexpressed by neurons of 
the rat lateral hypothalamic area. Neurosci. Lett. 1999, 259, 153–156. 
(20) Reti, I. M.; Reddy, R.; Worley, P. F.; Baraban, J. M. Selective expression of Narp, a 
secreted neuronal pentraxin, in orexin neurons. J. Neurochem. 2002, 82, 1561–1565. 
(21) Abrahamson, E. E.; Leak, R. K.; Moore, R. Y. The suprachiasmatic nucleus projects to 
posterior hypothalamic arousal systems. Neuroreport. 2001, 12, 435–440.  
(22) Rosin, D.L.; Weston, M. C.; Sevigny, C. P.; Stornetta, R. L.; Guyenet, P. G. 
Hypothalamic orexin (hypocretin) neurons express vesicular glutamate transporters VGLUT1 
or VGLUT2. J. Comp. Neurol. 2003, 465, 593–603. 
68 
 
(23) Torrealba, F.; Yanagisawa, M.; Saper, C. B. Colocalization of orexin a and glutamate 
immunoreactivity in axon terminals in the tuberomammillary nucleus in rats. Neuroscience 
2003, 119, 1033–1044. 
(24) Scammel, T. E.; Saper, C. P. Orexins: looking forward to sleep, back at addiction. Nat. 
Med. 2007, 13, 126–128. 
 (25) Brisbare-Roch, C.; Dingemanse, J.; Koberstein, R.; Hoever, P.; Aissaoui, H.; Flores, S.; 
Mueller, C.; Nayler, O.; van Gerven, J.; de Haas, S. L.; Hess, P.; Qiu, C.; Buchmann, S.; 
Scherz, M.; Weller, T.; Fischli, W.; Clozel, M.; Jenck, F. Promotion of sleep by targeting the 
orexin system in rats, dogs and humans. Nat. Med. 2007, 13, 150–155. 
(26) Thompson, J. L.; Borgland, S. L. A role for hypocretin/orexin in motivation. Behav. 
Brain Res. 2011, 217, 446–453. 
(27) Nishino, S. Chapter 47 - Hypothalamus, hypocretins/orexin, and vigilance control. 
Handb. Clin. Neurol. 2011, 99, 765–782. 
(28) Peyron, C.; Faraco, J.; Rogers, W.; Ripley, B.; Overeem, S.; Charnay, Y.; Reynolds D, 
Albin, R.; Li, R.; Hungs, M.; Pedrazzoli, M.; Padigaru, M.; Kucherlapati, M.; Fan, J.; Maki, 
R.; Lammers, G. J.; Bouras, C.; Kucherlapati, R.; Nishino, S.; Mignot, E. A mutation in a case 
of early onset narcolepsy and a generalized absence of hypocretin peptides in human 
narcoleptic brains. Nat Med. 2000, 9, 991–997. 
69 
 
(29) Thannickal, T. C.; Moore, R. Y.; Nienhuis, R.; Ramanathan, L.; Gulyani, S.; Aldrich, 
M.; Cornford, M.; Siegel, J. M. Reduced number of hypocretin neurons in human narcolepsy. 
Neuron 2000, 27, 469–474. 
(30) Mignot, E.; Lammers G. J.; Ripley, B.; Okun, M.; Nevsimalova, S.; Overeem, S.; 
Vankova, J.; Black, J.; Harsh, J.; Bassetti, C.; Schrader, H.; Nishino, S. The role of 
cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other 
hypersomnias. Arch. Neurol. 2002, 59, 1553–1562. 
(31) Zhang, J.; Li, B; Yu, L.; He, Y. -C.; Li, H. -Z.; Zhu, J. -N.; Wang, J. -J. A role for 
orexin in central vestibular motor control. Neuron 2011, 69, 793–804.  
 (32) Okumura, T.; Nozu, T. Role of brain orexin in the pathophysiology of functional 
gastrointestinal disorders. J. Gastroenterol. Hepatol. 2011, 26, 61–66. 
 (33) Sakurai, T. Orexins and orexin receptors: implication in feeding behavior. Regul. Pept. 
1999, 85, 25–30. 
(34) Schuld, A.; Hebebrand, J.; Geller, F.; Pollmacher, T. Increased body-mass index in 
patients with narcolepsy. Lancet 2000, 1274–1275. 
(35) Honda, Y.; Doi, Y.; Ninomiya, R.; Ninomiya, C. Increased frequency of 
non-insulin-dependent diabetes mellitus among narcoleptic patients. Sleep 1986, 9, 254–259. 
70 
 
(36) Lammers, G. J.; Pijl, H.; Iestra, J.; Langius, J. A.; Buunk, G.; Meinders, A. E. 
Spontaneous food choice in narcolepsy. Sleep 1996, 19, 75–76. 
(37) Sharf, R.; Sarhan, M.; Dileone, R. J. Role of orexin/hypocretin in dependence and 
addiction. Brain Res. 2010, 1314, 130–138. 
 (38) Chemelli, R. M.; Willie, J. T., Sinton, C, M.; Elmquist, J. K.; Scammell, T.; Lee, C.; 
Richardson, J. A.; Williams, S. C.; Xiong, Y.; Kisanuki, Y.; Fitch, T. E.; Nakazato, M.; 
Hammer, R. E.; Saper, C. B.; Yanagisawa, M. Narcolepsy in orexin knockout mice: 
molecular genetics of sleep regulation. Cell 1999, 98, 437–451. 
(39) Lin, L.; Faraco, J.; Li, R.; Kadotani, H.; Rogers, W.; Lin, X.; Qiu, X.; de Jong, P. J.; 
Nishino, S.; Mignot, E. The sleep disorder canine narcolepsy is caused by a mutation 
in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98, 365–376. 
 (40) Hara, J.; Beuckmann, C. T.; Nambu, T.; Willie, J. T.; Chemelli, R. M.; Sinton, C. M.; 
Sugiyama, F.; Yagami, K.; Goto, K.; Yanagisawa, M.; Sakurai, T. Genetic ablation of orexin 
neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001, 30, 345–354. 
 (41) Nishino, S.; Ripley, B.; Overeem, S.; Lammers, G. J.; Mignot, E. Hypocretin (orexin) 
deficiency in human narcolepsy. Lancet 2000, 355, 39–40. 
 (42) Harris, G. C.; Wimmer, M.; Aston-Jones, G. A role for lateral hypothalamic orexin 
neurons in reward seeking. Nature 2005, 437, 556–559. 
71 
 
 (43) Narita, M.; Nagumo, Y.; Hashimoto, S.; Khotib, J.; Miyatake, M.; Sakurai, T.; 
Yanagisawa, M.; Nakamachi, T.; Shioda, S.; Suzuki, T. Direct involvement of orexinergic 
systems in the activation of the mesolimbic dopamine pathway and related behaviors induced 
by morphine. J. Neurosci. 2006, 26, 398–405. 
(44) Hara, J.; Yanagisawa, M.; Sakurai, T. Difference in obesity phenotype between 
orexin-knockout mice and orexin neuron-deficient mice with same genetic background and 
environmental conditions. Neurosci. Lett. 2005, 380, 239–242. 
(45) Coleman, P. J.; Renger, J. J. Orexin receptor antagonists: a review of promising 
compounds patented since 2006. Expert. Opin. Ther. Pat. 2010, 20, 307–324. 
(46) Bingham, M. J.; Cai, J.; Deehan, M. R. Eating, sleeping and rewarding: orexin receptors 
and their antagonists. Curr. Opin. Drug. Discov. Devel. 2006, 9, 551–559. 
 (47) Boss, C.; Brisbare-Roch, C.; Jenck, F. Biomedical application of orexin/hypocretin 
receptor ligands in neuroscience. J. Med. Chem. 2009, 52, 891–903. 
(48) Cai, J.; Cooke, F. E.; Sherborne, B. S. Antagonists of the orexin receptors. Curr. Opin. 
Drug. Discov. Devel. 2006, 16, 631–646. 
 (49) Roecker, A. J.; Coleman, P. J. Orexin receptor antagonists: medicinal chemistry and 
therapeutic potential. Curr. Top. Med. Chem. 2008, 8, 977–987. 
72 
 
 (50) Gatfield, J.; Brisbare-Roch, C.; Jenck, F.; Boss, C. Orexin receptor antagonists: a new 
concept in CNS disorders? Chem. Med. Chem. 2010, 5, 1197–1214. 
(51) Winrow. C. J.; Gotter, A. L.; Cox, C. D.; Doran, S. M.; Tannenbaum, P. L.; Breslin, M. 
J.; Garson, S. L.; Fox, S. V.; Harrell, C. M.; Stevens, J.; Reiss, D. R.; Cui, D.; Coleman, P. J.; 
Renger, J. J. Promotion of sleep by suvorexant - a novel dual orexin receptor antagonist. J. 
Neurogenet. 2011, 25, 52–61.  
(52) Smart, D.; Sabido-David, C.; Brough, S. J.; Jewitt, F.; Johns, A.; Porter, R. A.; Jerman, 
J. C.  SB-334867-A: the first selective orexin-1 receptor antagonist. Br. J. Pharmacol. 2001, 
132, 1179-82. 
(53) Porter, R. A.; Chan, W. N.; Coulton, S.; Johns, A.; Hadley, M. S.; Widdowson, K.; 
Jerman, J. C.; Brough, S. J.; Coldwell, M.; Smart, D.; Jewitt, F.; Jeffrey, P.; Austin, N. 
1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorg. Med. 
Chem. 2001, 11, 1907–1910. 
(54) Boutrel, B.; Kenny, P. J.; Specio, S. E.; Martin-Fardon, R.; Markou, A.; Koob, G. F.; de 
Lecea, L. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking 
behavior. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 19168–173. 
(55) Borgland, S. L.; Taha, S. A.; Sarti, F.; Fields, H. L.; Bonci, A. Orexin A in the VTA is 
critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron 
73 
 
2006, 49, 589–601. 
(56) Hollander, J. A.; Lu, Q.; Cameron, M. D.; Kamenecka, T. M.; Kenny, P, J. Insular 
hypocretin transmission regulates nicotine reward. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 
19480–485. 
(57) Malherbe, P.; Borroni, E.; Pinard, E.; Wettstein, J. G.; Knoflach, F. Biochemical and 
electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 
receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists. Mol. 
Pharmacol. 2009, 76, 618–31. 
 (58) Malherbe, P.; Borroni, E.; Gobbi, L.; Knust, H.; Nettekoven, M.; Pinard, E.; Roche, O.; 
Rogers-Evans, M.; Wettstein, J. G.; Moreau, J. L. Biochemical and behavioural 
characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. 
Br. J. Pharmacol. 2009, 156, 1326–1341. 
(59) Langmead, C. J.; Jerman, J. C.; Brough, S. J.; Scott, C.; Porter, R. A.; Herdon, H. J. 
Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the 
human orexin-1 receptor. Br. J. Pharmacol. 2004 ,141, 340–346. 
(60) Liu, F.; Majo, V. J.; Prabhakaran, J.; Castrillion, J.; Mann, J. J.; Martinez, D.; Kumar, J. 
S. D. Radiosynthesis of [11C]BBAC and [11C]BBPC as potential PET tracers for orexin2 
receptors. Bioorg. Med. Chem. Lett. 2012, 22, 2172–2174. 
74 
 
 (61) Wang, C.; Moseley, C. K.; Carlin, S. M.; Wilson, C. M.; Neelamegam, R.; Hooker, J. 
M. Radiosynthesis and evaluation of [11C]EMPA as a potential PET tracer for orexin 2 
receptors. Bioorg. Med. Chem. 2013, 23, 3389–3392. 
(62) Wang, C.; Wilson, C. M.; Moseley, C. K.; Carlin, S. M.; Hsu, S.; Arabasz, G.; 
Schroeder, F. A.; Sander, C. Y.; Hooker, J. M. Evaluation of potential PET imaging probes 
for the orexin 2 receptors. Nucl Med Biol. 2013, 40, 1000-1005. 
(63) Terauchi, T.; Takemura, A.; Doko, T.; Yoshida, Y.; Tanaka, T.; Sorimachi, K.; Naoe, 
Y.; Beuckmann, C.; Kazuta, Y. Cyclopropane compound. 2010, WO 2012/039371 A1. 
(64) Kazuta, Y.; Tsujita, R.; Yamashita, K.; Uchino, S.; Kohsaka, S.; Matsuda, A.; Shuto, S. 
Synthesis of derivatives of (1S,2R)-1-phenyl-2-[(S)-1- 
aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) modified at the 1-aromatic 
moiety as novel NMDA receptor antagonists: The aromatic group is essential for the activity. 
Bioorg. Med. Chem. 2002, 10, 3829–3848. 
 (65) Suzuki, K.; Inoue, O.; Hashimoto, K.; Yamasaki, T.; Kuchiki, M.; Tamate, K. 
Computer-controlled large scale production of high specific activity [11C]RO 15-1788 for 
PET studies of benzodiazepine receptors. Int. J. Appl. Radiat. Isot. 1985, 36, 971–976.  
(66) Adachi, Y.; Suzuki, H.; Sugiyama, Y. Comparative studies on in vitro methods for 
evaluating in vivo function of MDR1 P-glycoprotein. Pharm. Res. 2001, 18, 1660–1668. 
75 
 
(67) Sugimoto, H.; Matsumoto, S.; Tachibana, M.; Niwa, S.; Hirabayashi, H.; Amano, N.; 
Moriwaki, T. Establishment of in vitro P-glycoprotein inhibition assay and its exclusion 
criteria to assess the risk of drug-drug interaction at the drug discovery stage. J. Pharm. Sci. 
2011, 100, 4013–4023. 
 (68) Iwata, R.; Ido, T.; Takahashi, T.; Nakanishi, H.; Iida, S. Optimization of [11C]HCN 
production and no-carrier-added [1-11C]amino acid synthesis. Int J Rad Appl Instrum A. 1987, 
38, 97–102. 
(69) Mathews, W. B.; Monn, J. A.; Ravert, H. T.; Holt, D. P.; Schoepp, D. D.; Dannals, R. F. 
Synthesis of a mGluR5 antagonist using [11C]copper(I) cyanide. J. Labelled. Compd. 
Radiopharm. 2006, 49, 829–834. 
(70) Coward, P.; Wada, H. G.; Falk, M. S.; Chan, S. D.; Meng, F.; Akil, H.; Conklin, B. R. 
Controlling signaling with a specifically designed Gi-coupled receptor. Proc. Natl. Acad. Sci. 
U.S.A. 1998, 95, 352–357. 
(71) Mintun, M. A.; Raichle, M. E.; Kilbourn, M. R.; Wooten, G. F.; Welch, M. J. A 
quantitative model for the in vivo assessment of drug binding sites with positron emission 
tomography. Ann. Neurol. 1984, 15, 217–227. 
(72) Eckelman, W. C.; Mathis, C. A. Targeting proteins in vivo: in vitro guidelines. Nuc.l 
Med. Biol. 2006, 33, 161–164. 
76 
 
(73) Eckelman, W. C.; Kilbourn, M. R.; Mathis, C. A. Discussion of targeting proteins in 
vivo: in vitro guidelines. Nucl. Med. Biol. 2006, 33, 449–451. 
(74) Guo, Q.; Brady, M.; Gunn, R. N. A biomathematical modeling approach to central 
nervous system radioligand discovery and development. J. Nucl. Med. 2009, 50, 1715–1723. 
(75) Tai, Y. C.; Ruangma, A.; Rowland, D.; Siegel, S.; Newport, D. F.; Chow, P. L.; 
Laforest, R. Performance evaluation of the microPET focus: a third-generation microPET 
scanner dedicated to animal imaging. J. Nucl. Med. 2005, 46, 455–463. 
(76) Watanabe, M.; Okada, H.; Shimizu, K.; Omura, T.; Yoshikawa, E.; Kosugi, T.; Mori, 
S.; Yamashita, T. A high resolution animal PET scanner using compact PS-PMT detectors. 
IEEE Trans Nucl Sci. 1997, 44, 1277–1282. 
(77) Yasuno, F.; Zoghbi, S. S.; Mccarron, J. A.; Hong, J.; Ichise, M.; Brown, A. K.; 
Gladding, R. L.; Bacher, J. D.; Pike, V. W.; Innis, R. B. Quantification of serotonin 5-HT1A 
receptors in monkey brain with [11C](R)-(–)-RWAY. Synapse 2006, 60, 510–520. 
(78) Batailler, M.; Mullier, A.; Sidibe A.; Delagrange, P.; Prévot, V.; Jockers, R; Migaud, M. 
Neuroanataomical distribution of the orphan GPR50 receptor in adult sheep and rodent brains. 
J. Neuroendocrinol. 2011, 23, 1365–2826. 
 
77 
 
9. Figures 
(A) 
 
(B) 
 
Figure 1. 6 (A) Schematic representation of the orexin system. Orexin-A and –B are derived 
from a common precursor peptide, prepro-orexin. The actions of orexins are mediated via two 
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G protein-coupled receptors named orexin-1 (OX1R) and orexin-2 (OX2R) receptors. OX1R is 
selective for orexin-A, whereas OX2R is a nonselective receptor for both orexin-A and 
orexin-B. OX1R is coupled exclusively to the Gq subclass of heterotrimeric G proteins, 
whereas OX2R may couple to Gi/o, and/or Gq. (B) Structures of mature orexin-A and -B 
peptides. The topology of the two intrachain disulfide bonds in orexin-A is indicated above 
the sequence. Amino acid identities are indicated by boxes. *Mammalian orexin-A sequences 
thus far identified (human, rat, mouse, pig, dog, sheep, cow) are all identical.
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Figure 2.6 Schematic drawing of para-agittal section through the rat brain, summarizing the 
organization of the orexin neuronal system. Orexin neurons are found only in the lateral 
hypothalamic area and project to the entire central nervous system. Abbreviations: 3V, third 
ventricle; 4V, fourth ventricle; Amyg, amygdala; VLPO, ventrolateral preoptic area; SCN, 
suprachiasmatic nucleus; PVN, paraventricular nucleus; VMH, ventromedial hypothalamus; 
ARC, arcuate nucleus, DMH, dorsomedial hypothalamus; LH, lateral hypothalamus; TMN, 
tuberomamillary nucleus; PPN, pedunculopontine nucleus; LC, locus coeruleus.
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Figure 3. Chemical structures of orexin receptor antagonists and radioligands 
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Figure 4. Chemical structures of PET tracer candidates and their 11C-labeling versions 
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Figure 5. Screening flow for PET tracer candidates.  
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Figure 6. Syntheses of common intermediate 18a 
aReagents and conditions: (a) NaHMDS, THF, 0 °C, 3 h, then KOH, EtOH, reflux, 8 h, then 
HCl, 0 °C–rt, 3 h; (b) NaBH4, MeOH–THF, 0 °C–rt, 1 h; (c) Novozym 435®, vinyl acetate, rt, 
17 h; (d) DIAD, PPh3, 0 °C–rt, 15 h, then NaOH, EtOH–H2O, rt, 1 h; (e) (COCl)2, DMSO, 
TEA, DCM, –60 °C–rt, 1 h, then 2-methyl-2-butene, NaClO2, NaH2PO4, acetone–H2O, rt, 14 
h. 
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Figure 7. Syntheses of 7a–12a and their radiolabeling precursors 7b–12ba 
 aReagents and conditions: (a) WSC, HOBt, NH4Cl, DIPEA, DMF, rt, 7 days; (b) 
2-chloro-5-fluoropyridine, K3PO4, Xant phos, Pd2(dba)3, dioxane, 80 °C, 1 day; (c) i: Br2, 
CHCl3, 0 °C–rt, 4 days; ii: AcONa, DMF, 50 °C, 2 h; iii: 1 M NaOH, MeOH, rt, 1.5 h, (d) 
pyridine–HCl salt, 120 °C, 2 h; (e) i: (COCl)2, DMF, DCM, rt, 1 h; ii: DIPEA, 
2-aminopyridines, THF, 60 °C, 1 h; (f) 2-amino-5-fluoropyridines, HATU, DIPEA, DMF, 0 
°C–rt, 3 h; (g) 5 M HCl, THF, rt, 2 h; (h) CH3I, Cs2CO3, DMF, rt, 2 h. 
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Figure 8. Radiosynthesis of [11C]7a–12aa 
 aReagents and conditions: (a) LiAlH4, THF, –15 °C, 2 min; (b) hydroiodic acid, 180 °C, 2 
min; (c) K2CO3, DMF, 50 °C, 3 min; (d) NaH, DMF, 40 °C, 3 min; (e) H2, Ni, 400 °C; (f) 
NH3, Pt, 960 °C; (g) Na2S2O5, CuSO4, H2O, 80 °C, 2 min; (h) DMF, 165 °C, 5 min. 
 
 
 
86 
 
 
  
Figure 9.1. HPLC analytic charts for 7a. Column: YMC Pack Pro C18, 4.6 mm ID ×150 mm; 
eluent: MeOH/H2O/TEA=7/3/0.01 (v/v/v); flow rate: 1.0 mL/min; Detector: UV-254 nm. 
 
 
Figure 9.2. HPLC analytic charts for 7b. Column: YMC Pack Pro C18, 4.6 mm ID ×150 mm; 
eluent: MeOH/H2O/TEA=7/3/0.01 (v/v/v); flow rate: 1.0 mL/min; Detector: UV-254 nm. 
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Figure 9.3. HPLC analytic charts for 8a. Column: YMC Pack Pro C18, 4.6 mm ID ×150 mm; 
eluent: MeCN/H2O/TEA=4/6/0.01 (v/v/v); flow rate: 1.5 mL/min; Detector: UV-254 nm. 
 
 
Figure 9.4. HPLC analytic charts for 8b. Column: YMC Pack Pro C18, 4.6 mm ID ×150 mm; 
eluent: MeCN/H2O/TEA=4/6/0.01 (v/v/v); flow rate: 1.5 mL/min; Detector: UV-254 nm. 
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Figure 9.5. HPLC analytic charts for 9a. Column: YMC Pack Pro C18, 4.6 mm ID ×150 mm; 
eluent: MeCN/H2O/TEA=4.5/5.5/0.01 (v/v/v); flow rate: 1.5 mL/min; Detector: UV-254 nm. 
 
 
Figure 9.6. HPLC analytic charts for 9b. Column: YMC Pack Pro C18, 4.6 mm ID ×150 mm; 
eluent: MeCN/H2O/TEA=4.5/5.5/0.01 (v/v/v); flow rate: 1.5 mL/min; Detector: UV-254 nm. 
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Figure 9.7. HPLC analytic charts for 10a. Column: YMC Pack Pro C18, 4.6 mm ID ×150 mm; 
eluent: MeCN/H2O/TEA=4.5/5.5/0.01 (v/v/v); flow rate: 1.5 mL/min; Detector: UV-254 nm. 
 
 
Figure 9.8. HPLC analytic charts for 10b. Column: YMC Pack Pro C18, 4.6 mm ID ×150 
mm; eluent: MeCN/H2O/TEA=4.5/5.5/0.01 (v/v/v); flow rate: 1.5 mL/min; Detector: UV-254 
nm. 
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Figure 9.9. HPLC analytic charts for 11a. Column: YMC Pack Pro C18, 4.6 mm ID ×150 mm; 
eluent: MeCN/H2O/TEA=4.5/5.5/0.01 (v/v/v); flow rate: 1.5 mL/min; Detector: UV-254 nm. 
 
 
Figure 9.10. HPLC analytic charts for 11b. Column: YMC Pack Pro C18, 4.6 mm ID ×150 
mm; eluent: MeCN/H2O/TEA=4.5/5.5/0.01 (v/v/v); flow rate: 1.5 mL/min; Detector: UV-254 
nm. 
 
91 
 
 
 
Figure 9.11. HPLC analytic charts for 12a. Column: YMC Pack Pro C18, 4.6 mm ID ×150 
mm; eluent: MeCN/H2O/TEA=4.5/5.5/0.01 (v/v/v); flow rate: 1.0 mL/min; Detector: UV-254 
nm. 
 
 
 
Figure 9.12. HPLC analytic charts for 12b.Column: YMC Pack Pro C18, 4.6 mm ID ×150 
mm; eluent: MeCN/H2O/TEA=4.5/5.5/0.01 (v/v/v); flow rate: 1.5 mL/min; Detector: UV-254 
nm. 
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Figure 10.1. HPLC purification charts for [11C]7a. Column: YMC Pack Pro C18, 10 mm ID 
×250 mm; eluent: MeOH/H2O/TEA=7/3/0.01 (v/v/v); flow rate: 4.0 mL/min; Detector: 
UV-254 nm (blue) and RI (red). 
 
Figure 10.2. HPLC purification charts for [11C]8a. Column: YMC Pack Pro C18, 10 mm ID 
×250 mm; eluent: MeCN/H2O/TEA=5/5/0.01 (v/v/v); flow rate: 5.0 mL/min; Detector: 
UV-254 nm (blue) and RI (red). 
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Figure 10.3. HPLC purification charts for [11C]9a. Column: YMC Pack Pro C18, 10 mm ID 
×250 mm; eluent: MeCN/H2O/TEA=4.5/5.5/0.01 (v/v/v); flow rate: 5.0 mL/min; Detector: 
UV-254 nm (blue) and RI (red). 
 
Figure 10.4. HPLC purification charts for [11C]10a. Column: YMC Pack Pro C18, 10 mm ID 
×250 mm; eluent: MeCN/H2O/TEA=5/5/0.01 (v/v/v); flow rate: 5.0 mL/min; Detector: 
UV-254 nm (blue) and RI (red). 
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Figure 10.5. HPLC purification charts for [11C]11a. Column: YMC Pack Pro C18, 10 mm ID 
×250 mm; eluent: MeCN/H2O/TEA=6/4/0.01 (v/v/v); flow rate: 5.0 mL/min; Detector: 
UV-254 nm (blue) and RI (red). 
 
Figure 10.6. HPLC purification charts for [11C]12a.Column: YMC Pack Pro C18, 10 mm ID 
×250 mm; eluent: MeCN/H2O/TEA=4.5/5.5/0.01 (v/v/v); flow rate: 5.0 mL/min; Detector: 
UV-254 nm (blue) and RI (red). 
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Figure 11.1. HPLC analytical charts for [11C]7a. Column: YMC Pack Pro C18, 4.6 mm ID 
×150 mm; eluent: MeOH/H2O/TEA=7/3/0.01 (v/v/v); flow rate: 1.0 mL/min; Detector: 
UV-254 nm (blue) and RI (red). 
 
 
Figure 11.2. HPLC analytical charts for [11C]8a. Column: YMC Pack Pro C18, 4.6 mm ID 
×150 mm; eluent: MeCN/H2O/TEA=4/6/0.01 (v/v/v); flow rate: 1.5 mL/min; Detector: 
UV-254 nm (blue) and RI (red). 
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Figure 11.3. HPLC analytical charts for [11C]9a. Column: YMC Pack Pro C18, 4.6 mm ID 
×150 mm; eluent: MeCN/H2O/TEA=4.5/5.5/0.01 (v/v/v); flow rate: 1.5 mL/min; Detector: 
UV-254 nm (blue) and RI (red). 
 
 
Figure 11.4. HPLC analytical charts for [11C]10a. Column: YMC Pack Pro C18, 4.6 mm ID 
×150 mm; eluent: MeCN/H2O/TEA=4.5/5.5/0.01 (v/v/v); flow rate: 1.5 mL/min; Detector: 
UV-254 nm (blue) and RI (red). 
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Figure 11.5. HPLC analytical charts for [11C]11a. Column: YMC Pack Pro C18, 4.6 mm ID 
×150 mm; eluent: MeCN/H2O/TEA=5/5/0.01 (v/v/v); flow rate: 1.5 mL/min; Detector: 
UV-254 nm (blue) and RI (red). 
 
 
Figure 11.6. HPLC analytical charts for [11C]12a. Column: YMC Pack Pro C18, 4.6 mm ID 
×150 mm; eluent: MeCN/H2O/TEA=4.5/5.5/0.01 (v/v/v); flow rate: 1.0 mL/min; Detector: 
UV-254 nm (blue) and RI (red).  
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Figure 12. Representative in vitro autoradiographic images of rat brains. Representative in 
vitro autoradiographic images of rat brains treated with [11C]7a (7.6 nM, A,B), [11C]8a (2.0 
nM, C,D), [11C]9a (2.5 nM, E,F), [11C]10a (59.0 nM, G,H), [11C]11a (1.6 nM, I,J), [11C]12a 
(2.6 nM, K,L), [3H]4 (5.0 nM, M,N). All coronal slices were collected about –4 mm from 
bregma. (A) [11C]7a only; (B) [11C]7a with 7a (10 μM); (C) [11C]8a only; (D) [11C]8a with 8a 
(10 μM); (E) [11C]9a only; (F) [11C]9a with 9a (10 μM); (G) [11C]10a only; (H) [11C]10a with 
10a (10 μM); (I) [11C]11a only; (J) [11C]11a with 11a (10 μM); (K) [11C]12a only; (L) 
[11C]12a with 12a (10 μM); (M) [3H]4 only; (N) [3H]4 with 4 (10 μM). 
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Figure 13. In vitro autoradiographic binding of [11C]9a to the rat neocortex in the absence 
(control) and presence of nonradioactive OXR ligands. (A) Total binding of [11C]9a (3.6 nM) 
to the cortical layer VI at baseline and in co-incubation with 4 (200 nM), 3 (20 μM) and 
unlabeled 9a (10 μM). (B) Inhibition of specific radioligand binding as percentage of 
inhibition by 10 μM of unlabeled 9a. We conceived that decrease of total [11C]9a binding in 
the presence of 10 μM of unlabeled 9a corresponds to the full abolishment of specific [11C]9a 
binding, and reduction of total binding in each condition was normalized by this full 
abolishment to determine inhibition of specific radioligand binding. 
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Figure 14. Rat PET study of [11C]9a. (A,B) Representative PET images of P-gp–knockout 
(A) and wild-type (B) rat brains generated by averaging dynamic data at 0–90 min after 
intravenous injection of [11C]9a. PET images are superimposed on a magnetic resonance 
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imaging (MRI) template. (C,D) Time–radioactivity curves for [11C]9a in the neocortex (CTX), 
hippocampus (HIP), thalamus (THA), and cerebellum (CER) of P-gp–knockout (C) and 
wild-type (D) rat brains (triplicated experiments). (E) Time–radioactivity curves for [11C]9 in 
the medial prefrontal cortex (MPFC), HIP, CTX, and CER of P-gp–knockout rat brains after 
blockade with 9a (10 mg/kg p.o., 1 h before radioligand injection). (F) Target-to-cerebellum 
ratio of AUC in the P-gp–knockout rat brain in control (closed bars) and blockade (open bars) 
experiments. The radioactivity is expressed as percentage of injected radioligand dose per unit 
volume of tissue (% ID/mL). 
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Figure 15. Rat PET study of [11C]8a. (A, B) Representative PET images of P-gp–knockout 
(A) and wild-type (B) rat brains generated by averaging dynamic data at 0–90 min after 
intravenous injection of [11C]8a. PET images are superimposed on an MRI template. (C, D) 
Time–radioactivity curves for [11C]8a in the medial prefrontal cortex (MPFC), hippocampus 
(HIP), neocortex (CTX), thalamus (THA), and cerebellum (CER) of P-gp–knockout (C) and 
wild-type (D) rat brains. 
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Figure 16. Rhesus monkey PET study of [11C]9a. (A,C) Orthogonal PET images of rhesus 
monkey brain generated by averaging dynamic scan data at 0–90 min after intravenous 
injection of [11C]9a. Orthogonal images at baseline (A) and under blockade of P-gp by 
pretreatment with tariquidar (8 mg/kg) at 0.25 h before radioligand injection (C) are 
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superimposed on individual MRI data. (B, D) Time–radioactivity curves for [11C]9a in the 
CTX, HIP, and CER of a rhesus monkey at baseline (B) and under P-gp blockade (D). 
Radioactivity is expressed as percentage of standardized uptake value (% SUV). 
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10. Tables 
Table 1. Pharmacological Properties of PET Tracer Candidates 
Ar1
Ar2
HN
OO
Ar1
Ar3
N
N
Ar2
F
MeO N
F
Ar3
7a
N
N
F N
F8a
OMe
N
N
F
N
F
9a
MeO
N
N
F
N
CN
10a
N
N
F
N
F
11a
OMe
12a
7
2
1
5
2
30
3
1
32
12
3.85
4.18
3.29
3.43
4.58
cLogPaOX2 Ki OX1 Ki
(nM) (nM)
compound
1.55
(1.24/0.80)
2.06
(2.45/1.19)
3.11
(2.61/0.84)
1.76
(1.92/1.09)
1.21
(0.98/0.81)
(MDR1 FR / PK1 FR)
corrected P-gp FRc
N
N
N
F
MeO
1 9 3.15 2.03(1.97/0.97)
3.32
2.93
2.97
d
3.60
LogDb
in vitro binding affinity lipophilicity
d
4 (EMPA)
3 (MK-4305)
3 993 3.43 3.48(4.28/1.23)
12 9 4.79 1.30(1.08/0.83)d
d
 
acLogP value was calculated by Daylight Software ver. 4.94 (Daylight Chemical Information 
Systems, Inc., Niguel, CA). bLogD values were quantified in n-octanol/phosphate buffer (pH 
7.4) by the shake-flask method (n = 3; maximum range, ± 5%). cSee Experimental Section 5. 
dNot determined. 
106 
 
Table 2. Purities of 7a–12a and Precursors 7b–12b Determined by HPLCa 
 
a see Figure 2 as follows. 
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Table 3. Quantitative Indices of Autoradiographic Ligand Binding 
 
 
Radioactivity was measured in the neocortical layer VI (arrowheads A and A’) and layers III - 
IV (arrowheads B and B’).
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 Table 4. GPCR Panel Assays to Determine Off-Target Activity of 10 μM of 9a. 
Against EC20 reference Against EC80 reference
Noradrenaline α1 Phenylephrin 81 93 84
Noradrenaline α2 UK 14304 110 114 87
Cannabinoid CB1 CP 55940 47 119 89
Dopamine D2 TNPA 109 100 96
Dopamine D4 TNPA 100 111 88
Free fatty acid FFA3 Propionic acid 124 105 82
Free fatty acid FFA4 Propionic acid 94 92 71
Histamine H1 Histamine 109 111 99
Histamine H3 Histamine 109 113 99
Histamine H4 Histamine 95 100 91
Opioid μ DAMGO 116 108 101
Opioid κ Dynorphin A 140 115 82
Melatonin MT1A Melatonin 5 26 69
Opioid δ β-Endorphin 91 108 81
Metabotropic glutamate type 2 Glutamate 100 116 79
Acetylcholine ACh1 Carbacol 115 123 122
Acetylcholine ACh2 Carbacol 113 128 115
Acetylcholine ACh3 Carbacol 86 123 147
Serotonin 1B α-Methylserotonin 103 90 77
Serotonin 2A α-Methylserotonin 99 110 83
Adenosine A1 N 6-cyclopentyladenosine 99 110 83
Adenosine A2A CGS 21680 100 107 145
Adenosine A2B NECA 92 95 130
Adenosine A3 IB-MECA 95 97 83
TNPA, R (-)-2,10,11-trihydroxy-N -n -propylnoraporphine; DAMGO, Tyr- D -Ala-Gly-N -methyl-Phe-Gly-ol; NECA, N -ethylcarboxamidoadenosine;
IB-MECA,  N 6-(3-iodobenzyl)adenosine-5-N -methyluronamide
Calcium signals (% of baseline)
Antagonistic activity assay
Agonistic activity assay
Target receptor Reference ligand
 
109 
 
Table 5. Fraction of Unchanged [11C]9a as Percentage of Total Radioactivity in 
P-gp–knockout Rat Plasma and Brain 
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